Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,29976060,bioavailability,Pharmacokinetic studies in rats showed an increase in the bioavailability of peptide 12 > 70-fold (from 0.58 ± 0.11% to 43.8 ± 14.9%) after applying the LPCM method to peptide 12 and converting it to the prodrug 12P.,Enhancing Oral Bioavailability of Cyclic RGD Hexa-peptides by the Lipophilic Prodrug Charge Masking Approach: Redirection of Peptide Intestinal Permeability from a Paracellular to Transcellular Pathway. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29976060/),%,0.58,1759,DB00335,Atenolol
,29976060,bioavailability,Pharmacokinetic studies in rats showed an increase in the bioavailability of peptide 12 > 70-fold (from 0.58 ± 0.11% to 43.8 ± 14.9%) after applying the LPCM method to peptide 12 and converting it to the prodrug 12P.,Enhancing Oral Bioavailability of Cyclic RGD Hexa-peptides by the Lipophilic Prodrug Charge Masking Approach: Redirection of Peptide Intestinal Permeability from a Paracellular to Transcellular Pathway. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29976060/),%,43.8,1760,DB00335,Atenolol
,14602188,area under the curve (AUC),"The area under the curve (AUC) was significantly higher in the enhancer group (12,402+/-3061 ng/ml.h) than that in the control group (8507+/-2092 ng/ml.h), showing about 46% increased bioavailability (P<0.05).",Enhanced bioavailability of atenolol by transdermal administration of the ethylene-vinyl acetate matrix in rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14602188/),[ng] / [h·ml],"12,402",2643,DB00335,Atenolol
,14602188,area under the curve (AUC),"The area under the curve (AUC) was significantly higher in the enhancer group (12,402+/-3061 ng/ml.h) than that in the control group (8507+/-2092 ng/ml.h), showing about 46% increased bioavailability (P<0.05).",Enhanced bioavailability of atenolol by transdermal administration of the ethylene-vinyl acetate matrix in rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14602188/),[ng] / [h·ml],8507,2644,DB00335,Atenolol
,14602188,C(max),"The average C(max) was increased in the enhancer group (1361+/-340 ng/ml) compared with the control group (1168+/-293 ng/ml), but not significantly.",Enhanced bioavailability of atenolol by transdermal administration of the ethylene-vinyl acetate matrix in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14602188/),[ng] / [ml],1361,2645,DB00335,Atenolol
,14602188,C(max),"The average C(max) was increased in the enhancer group (1361+/-340 ng/ml) compared with the control group (1168+/-293 ng/ml), but not significantly.",Enhanced bioavailability of atenolol by transdermal administration of the ethylene-vinyl acetate matrix in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14602188/),[ng] / [ml],1168,2646,DB00335,Atenolol
,14602188,T(max),The T(max) was significantly decreased in the enhancer group (1.3+/-0.36 h) compared with the control group (2.0+/-0.51 h).,Enhanced bioavailability of atenolol by transdermal administration of the ethylene-vinyl acetate matrix in rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14602188/),h,1.3,2647,DB00335,Atenolol
,14602188,T(max),The T(max) was significantly decreased in the enhancer group (1.3+/-0.36 h) compared with the control group (2.0+/-0.51 h).,Enhanced bioavailability of atenolol by transdermal administration of the ethylene-vinyl acetate matrix in rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14602188/),h,2.0,2648,DB00335,Atenolol
,14602188,absolute bioavailability,"The absolute bioavailability was 19.7% in the control group, 28.6% in the enhancer group and 77.4% in the oral administration group compared with IV the group.",Enhanced bioavailability of atenolol by transdermal administration of the ethylene-vinyl acetate matrix in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14602188/),%,19.7,2649,DB00335,Atenolol
,14602188,absolute bioavailability,"The absolute bioavailability was 19.7% in the control group, 28.6% in the enhancer group and 77.4% in the oral administration group compared with IV the group.",Enhanced bioavailability of atenolol by transdermal administration of the ethylene-vinyl acetate matrix in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14602188/),%,28.6,2650,DB00335,Atenolol
,14602188,absolute bioavailability,"The absolute bioavailability was 19.7% in the control group, 28.6% in the enhancer group and 77.4% in the oral administration group compared with IV the group.",Enhanced bioavailability of atenolol by transdermal administration of the ethylene-vinyl acetate matrix in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14602188/),%,77.4,2651,DB00335,Atenolol
,6626700,final elimination phase half-life,After intravenous administration at 200 mg the blood levels of parent drug were found to decay tri-exponentially with a final elimination phase half-life of about 4.5 h.,Pharmacokinetic studies with atenolol in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6626700/),h,4.5,2655,DB00335,Atenolol
,6626700,volume of distribution for the central compartment,The volume of distribution for the central compartment was 40 per cent body weight and the whole body volume of distribution was 160 per cent body weight.,Pharmacokinetic studies with atenolol in the dog. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6626700/),%,40,2656,DB00335,Atenolol
,6626700,volume of distribution,The volume of distribution for the central compartment was 40 per cent body weight and the whole body volume of distribution was 160 per cent body weight.,Pharmacokinetic studies with atenolol in the dog. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6626700/),%,160,2657,DB00335,Atenolol
,6626700,percentage urinary recovery,The percentage urinary recovery of parent drug was 83 per cent.,Pharmacokinetic studies with atenolol in the dog. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6626700/),%,83,2658,DB00335,Atenolol
,6626700,percentage urinary recovery,Following oral dosing at 400 mg (as a solution and as a clinical trial tablet) the percentage urinary recovery was 65 per cent and the half-life extended slightly to between 5 and 6 h.,Pharmacokinetic studies with atenolol in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6626700/),%,65,2659,DB00335,Atenolol
,6626700,half-life,Following oral dosing at 400 mg (as a solution and as a clinical trial tablet) the percentage urinary recovery was 65 per cent and the half-life extended slightly to between 5 and 6 h.,Pharmacokinetic studies with atenolol in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6626700/),h,5 and 6,2660,DB00335,Atenolol
,6626700,peak blood levels,The peak blood levels were however very similar for the two formulations (17 and 15 micrograms/ml for the solution and tablet respectively) and occurred at the same time (1-2 h after dosing).,Pharmacokinetic studies with atenolol in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6626700/),[μg] / [ml],17,2661,DB00335,Atenolol
,6626700,peak blood levels,The peak blood levels were however very similar for the two formulations (17 and 15 micrograms/ml for the solution and tablet respectively) and occurred at the same time (1-2 h after dosing).,Pharmacokinetic studies with atenolol in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6626700/),[μg] / [ml],15,2662,DB00335,Atenolol
,6626700,total ares under the blood concentration time curves,The total ares under the blood concentration time curves were similar and the values (100 and 104 micrograms/ml-1 h respectively) agreed well with that anticipated on the basis of the intravenous data.,Pharmacokinetic studies with atenolol in the dog. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6626700/),[μg] / [ml],100,2663,DB00335,Atenolol
,6626700,total ares under the blood concentration time curves,The total ares under the blood concentration time curves were similar and the values (100 and 104 micrograms/ml-1 h respectively) agreed well with that anticipated on the basis of the intravenous data.,Pharmacokinetic studies with atenolol in the dog. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6626700/),[μg] / [ml],104,2664,DB00335,Atenolol
,27061492,limits of detection (S/N,"The limits of detection (S/N = 3) and quantification (S/N = 10) were 0.5 and 2 ng/mL, respectively.",Determination of atenolol in human plasma using ionic-liquid-based ultrasound-assisted in situ solvent formation microextraction followed by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27061492/),,3,3299,DB00335,Atenolol
,27061492,S/N,"The limits of detection (S/N = 3) and quantification (S/N = 10) were 0.5 and 2 ng/mL, respectively.",Determination of atenolol in human plasma using ionic-liquid-based ultrasound-assisted in situ solvent formation microextraction followed by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27061492/),[ng] / [ml],10,3300,DB00335,Atenolol
,27061492,S/N,"The limits of detection (S/N = 3) and quantification (S/N = 10) were 0.5 and 2 ng/mL, respectively.",Determination of atenolol in human plasma using ionic-liquid-based ultrasound-assisted in situ solvent formation microextraction followed by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27061492/),[ng] / [ml],0.5,3301,DB00335,Atenolol
,27061492,S/N,"The limits of detection (S/N = 3) and quantification (S/N = 10) were 0.5 and 2 ng/mL, respectively.",Determination of atenolol in human plasma using ionic-liquid-based ultrasound-assisted in situ solvent formation microextraction followed by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27061492/),[ng] / [ml],2,3302,DB00335,Atenolol
,27061492,relative recovery,"A reasonable relative recovery range of 90-96.7% and satisfactory intra-assay (4.8-5.1%, n = 6) and interassay (5.0-5.6%, n = 9) precision along with a substantial sample clean-up demonstrated good performance of the procedure.",Determination of atenolol in human plasma using ionic-liquid-based ultrasound-assisted in situ solvent formation microextraction followed by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27061492/),%,90-96.7,3303,DB00335,Atenolol
,16543910,AUC,"The AUC of glucose in rilmenidine group decreased from 860+/-93 to 737+/-66 mmol/min/l (P<0.05), and in the atenolol group it increased from 937+/-86 to 989+/-88 mmol/min/l (P<0.05).",How can we block sympathetic overactivity? Effects of rilmenidine and atenolol in overweight hypertensive patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16543910/),[mM] / [l·min],860,4542,DB00335,Atenolol
,16543910,AUC,"The AUC of glucose in rilmenidine group decreased from 860+/-93 to 737+/-66 mmol/min/l (P<0.05), and in the atenolol group it increased from 937+/-86 to 989+/-88 mmol/min/l (P<0.05).",How can we block sympathetic overactivity? Effects of rilmenidine and atenolol in overweight hypertensive patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16543910/),[mM] / [l·min],737,4543,DB00335,Atenolol
,16543910,AUC,"The AUC of glucose in rilmenidine group decreased from 860+/-93 to 737+/-66 mmol/min/l (P<0.05), and in the atenolol group it increased from 937+/-86 to 989+/-88 mmol/min/l (P<0.05).",How can we block sympathetic overactivity? Effects of rilmenidine and atenolol in overweight hypertensive patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16543910/),[mM] / [l·min],937,4544,DB00335,Atenolol
,16543910,AUC,"The AUC of glucose in rilmenidine group decreased from 860+/-93 to 737+/-66 mmol/min/l (P<0.05), and in the atenolol group it increased from 937+/-86 to 989+/-88 mmol/min/l (P<0.05).",How can we block sympathetic overactivity? Effects of rilmenidine and atenolol in overweight hypertensive patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16543910/),[mM] / [l·min],989,4545,DB00335,Atenolol
,2076652,Pulse similarly,Pulse similarly decreased significantly from 93.9 +/- 15.7 to 77.8 +/- 10.5.,Pharmacokinetics and clinical effects of atenolol in therapy of hyperthyroidism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076652/),,93.9,4721,DB00335,Atenolol
,2076652,Pulse similarly,Pulse similarly decreased significantly from 93.9 +/- 15.7 to 77.8 +/- 10.5.,Pharmacokinetics and clinical effects of atenolol in therapy of hyperthyroidism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076652/),,77.8,4722,DB00335,Atenolol
,9266287,Tmax,"Arithmetic mean for individual Tmax differences was 0.8 h, and the 90% confidence interval did not include the zero value.",Comparative bioavailability of two atenolol tablet formulations in healthy male volunteers after a single dose administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9266287/),h,0.8,9095,DB00335,Atenolol
,590303,half-life,In patients with normal renal function the atenolol half-life was calculated to be about six hours following single 100 mg oral doses.,Pharmacokinetics of atenolol in patients with renal impairment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/590303/),h,six,9515,DB00335,Atenolol
,3358897,Cmax,2. The peak plasma concentrations (Cmax) and areas under the plasma concentration-time curves (AUC) of verapamil were similar during combined treatment with propranolol (mean +/- s.d.: Cmax = 491 +/- 397 ng ml-1; AUC = 2075 +/- 1524 ng ml-1 h) or atenolol (mean +/- s.d.: Cmax = 372 +/- 320 ng ml-1; AUC = 1985 +/- 1660 ng ml-1 h).,The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358897/),[ng] / [ml],491,18517,DB00335,Atenolol
,3358897,AUC,2. The peak plasma concentrations (Cmax) and areas under the plasma concentration-time curves (AUC) of verapamil were similar during combined treatment with propranolol (mean +/- s.d.: Cmax = 491 +/- 397 ng ml-1; AUC = 2075 +/- 1524 ng ml-1 h) or atenolol (mean +/- s.d.: Cmax = 372 +/- 320 ng ml-1; AUC = 1985 +/- 1660 ng ml-1 h).,The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358897/),[h·ng] / [ml],2075,18518,DB00335,Atenolol
,3358897,Cmax,2. The peak plasma concentrations (Cmax) and areas under the plasma concentration-time curves (AUC) of verapamil were similar during combined treatment with propranolol (mean +/- s.d.: Cmax = 491 +/- 397 ng ml-1; AUC = 2075 +/- 1524 ng ml-1 h) or atenolol (mean +/- s.d.: Cmax = 372 +/- 320 ng ml-1; AUC = 1985 +/- 1660 ng ml-1 h).,The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358897/),[ng] / [ml],372,18519,DB00335,Atenolol
,3358897,AUC,2. The peak plasma concentrations (Cmax) and areas under the plasma concentration-time curves (AUC) of verapamil were similar during combined treatment with propranolol (mean +/- s.d.: Cmax = 491 +/- 397 ng ml-1; AUC = 2075 +/- 1524 ng ml-1 h) or atenolol (mean +/- s.d.: Cmax = 372 +/- 320 ng ml-1; AUC = 1985 +/- 1660 ng ml-1 h).,The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358897/),[h·ng] / [ml],1985,18520,DB00335,Atenolol
,3358897,Cmax,3. No differences in Cmax and AUC were observed during verapamil monotherapy (mean +/- s.d.: Cmax = 287 +/- 105 ng ml-1; AUC = 1375 +/- 455 ng ml-1 h) vs combined treatment with propranolol (mean +/- s.d.: Cmax = 312 +/- 55 ng ml-1; AUC = 1566 +/- 486 ng ml-1 h).,The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358897/),[ng] / [ml],287,18521,DB00335,Atenolol
,3358897,AUC,3. No differences in Cmax and AUC were observed during verapamil monotherapy (mean +/- s.d.: Cmax = 287 +/- 105 ng ml-1; AUC = 1375 +/- 455 ng ml-1 h) vs combined treatment with propranolol (mean +/- s.d.: Cmax = 312 +/- 55 ng ml-1; AUC = 1566 +/- 486 ng ml-1 h).,The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358897/),[h·ng] / [ml],1375,18522,DB00335,Atenolol
,3358897,Cmax,3. No differences in Cmax and AUC were observed during verapamil monotherapy (mean +/- s.d.: Cmax = 287 +/- 105 ng ml-1; AUC = 1375 +/- 455 ng ml-1 h) vs combined treatment with propranolol (mean +/- s.d.: Cmax = 312 +/- 55 ng ml-1; AUC = 1566 +/- 486 ng ml-1 h).,The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358897/),[ng] / [ml],312,18523,DB00335,Atenolol
,3358897,AUC,3. No differences in Cmax and AUC were observed during verapamil monotherapy (mean +/- s.d.: Cmax = 287 +/- 105 ng ml-1; AUC = 1375 +/- 455 ng ml-1 h) vs combined treatment with propranolol (mean +/- s.d.: Cmax = 312 +/- 55 ng ml-1; AUC = 1566 +/- 486 ng ml-1 h).,The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358897/),[h·ng] / [ml],1566,18524,DB00335,Atenolol
,3358897,Cmax,"4. Treatment with verapamil increased the Cmax (mean +/- s.d.: 227 +/- 117 vs 116 +/- 62 ng ml-1, P less than 0.05) and AUC (1389 +/- 617 vs 837 +/- 316 ng ml-1 h, P = 0.0625) of propranolol in all subjects.",The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358897/),[ng] / [ml],227,18525,DB00335,Atenolol
,3358897,Cmax,"4. Treatment with verapamil increased the Cmax (mean +/- s.d.: 227 +/- 117 vs 116 +/- 62 ng ml-1, P less than 0.05) and AUC (1389 +/- 617 vs 837 +/- 316 ng ml-1 h, P = 0.0625) of propranolol in all subjects.",The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358897/),[ng] / [ml],116,18526,DB00335,Atenolol
,3358897,AUC,"4. Treatment with verapamil increased the Cmax (mean +/- s.d.: 227 +/- 117 vs 116 +/- 62 ng ml-1, P less than 0.05) and AUC (1389 +/- 617 vs 837 +/- 316 ng ml-1 h, P = 0.0625) of propranolol in all subjects.",The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358897/),[h·ng] / [ml],1389,18527,DB00335,Atenolol
,3358897,AUC,"4. Treatment with verapamil increased the Cmax (mean +/- s.d.: 227 +/- 117 vs 116 +/- 62 ng ml-1, P less than 0.05) and AUC (1389 +/- 617 vs 837 +/- 316 ng ml-1 h, P = 0.0625) of propranolol in all subjects.",The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358897/),[h·ng] / [ml],837,18528,DB00335,Atenolol
,6116195,half-life,"After oral administration, the pharmacological half-life (time required for 50% recovery of beta-blocking action) was 15.8 +/- 4.5 h for propranolol (3 mg/kg), 21.8 +/- 6.4 h for D-32 (0.5 mg/kg), 30.5 +/- 3.1 h for atenolol (6 mg/kg) and 30-35 h for pindolol (0.2 mg/kg).","Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116195/),h,15.8,21283,DB00335,Atenolol
,6116195,half-life,"After oral administration, the pharmacological half-life (time required for 50% recovery of beta-blocking action) was 15.8 +/- 4.5 h for propranolol (3 mg/kg), 21.8 +/- 6.4 h for D-32 (0.5 mg/kg), 30.5 +/- 3.1 h for atenolol (6 mg/kg) and 30-35 h for pindolol (0.2 mg/kg).","Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116195/),h,21.8,21284,DB00335,Atenolol
,6116195,half-life,"After oral administration, the pharmacological half-life (time required for 50% recovery of beta-blocking action) was 15.8 +/- 4.5 h for propranolol (3 mg/kg), 21.8 +/- 6.4 h for D-32 (0.5 mg/kg), 30.5 +/- 3.1 h for atenolol (6 mg/kg) and 30-35 h for pindolol (0.2 mg/kg).","Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116195/),h,30.5,21285,DB00335,Atenolol
,6116195,half-life,"After oral administration, the pharmacological half-life (time required for 50% recovery of beta-blocking action) was 15.8 +/- 4.5 h for propranolol (3 mg/kg), 21.8 +/- 6.4 h for D-32 (0.5 mg/kg), 30.5 +/- 3.1 h for atenolol (6 mg/kg) and 30-35 h for pindolol (0.2 mg/kg).","Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116195/),h,30-35,21286,DB00335,Atenolol
,6116195,time required for 50% recovery of beta,"After oral administration, the pharmacological half-life (time required for 50% recovery of beta-blocking action) was 15.8 +/- 4.5 h for propranolol (3 mg/kg), 21.8 +/- 6.4 h for D-32 (0.5 mg/kg), 30.5 +/- 3.1 h for atenolol (6 mg/kg) and 30-35 h for pindolol (0.2 mg/kg).","Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116195/),h,15.8,21287,DB00335,Atenolol
,6116195,time required for 50% recovery of beta,"After oral administration, the pharmacological half-life (time required for 50% recovery of beta-blocking action) was 15.8 +/- 4.5 h for propranolol (3 mg/kg), 21.8 +/- 6.4 h for D-32 (0.5 mg/kg), 30.5 +/- 3.1 h for atenolol (6 mg/kg) and 30-35 h for pindolol (0.2 mg/kg).","Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116195/),h,21.8,21288,DB00335,Atenolol
,6116195,time required for 50% recovery of beta,"After oral administration, the pharmacological half-life (time required for 50% recovery of beta-blocking action) was 15.8 +/- 4.5 h for propranolol (3 mg/kg), 21.8 +/- 6.4 h for D-32 (0.5 mg/kg), 30.5 +/- 3.1 h for atenolol (6 mg/kg) and 30-35 h for pindolol (0.2 mg/kg).","Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116195/),h,30.5,21289,DB00335,Atenolol
,6116195,time required for 50% recovery of beta,"After oral administration, the pharmacological half-life (time required for 50% recovery of beta-blocking action) was 15.8 +/- 4.5 h for propranolol (3 mg/kg), 21.8 +/- 6.4 h for D-32 (0.5 mg/kg), 30.5 +/- 3.1 h for atenolol (6 mg/kg) and 30-35 h for pindolol (0.2 mg/kg).","Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116195/),h,30-35,21290,DB00335,Atenolol
,6116195,half-life,"The pharmacological half-life after i.v. administration was 4.4 +/- 0.7 h for propranolol (300 microgram/kg) and 5.9 +/- 0.4 h for D-32 (150 microgram/kg), whereas the serum half-like (time required for 50% decrease in serum concentration) of propranolol was 1.4 h and that of D-32 was 1.3 h.","Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116195/),h,4.4,21291,DB00335,Atenolol
,6116195,half-life,"The pharmacological half-life after i.v. administration was 4.4 +/- 0.7 h for propranolol (300 microgram/kg) and 5.9 +/- 0.4 h for D-32 (150 microgram/kg), whereas the serum half-like (time required for 50% decrease in serum concentration) of propranolol was 1.4 h and that of D-32 was 1.3 h.","Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116195/),h,5.9,21292,DB00335,Atenolol
,6116195,serum half-like,"The pharmacological half-life after i.v. administration was 4.4 +/- 0.7 h for propranolol (300 microgram/kg) and 5.9 +/- 0.4 h for D-32 (150 microgram/kg), whereas the serum half-like (time required for 50% decrease in serum concentration) of propranolol was 1.4 h and that of D-32 was 1.3 h.","Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116195/),h,1.4,21293,DB00335,Atenolol
,6116195,serum half-like,"The pharmacological half-life after i.v. administration was 4.4 +/- 0.7 h for propranolol (300 microgram/kg) and 5.9 +/- 0.4 h for D-32 (150 microgram/kg), whereas the serum half-like (time required for 50% decrease in serum concentration) of propranolol was 1.4 h and that of D-32 was 1.3 h.","Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116195/),h,1.3,21294,DB00335,Atenolol
,7608315,Maximal concentration,"Maximal concentration was 343 +/- 120 micrograms/L, and the mean half-life was 4.72 hours.",Absorption pharmacokinetics of atenolol in patients with the Marfan syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7608315/),[μg] / [l],343,22889,DB00335,Atenolol
,7608315,half-life,"Maximal concentration was 343 +/- 120 micrograms/L, and the mean half-life was 4.72 hours.",Absorption pharmacokinetics of atenolol in patients with the Marfan syndrome. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7608315/),h,4.72,22890,DB00335,Atenolol
,428185,terminal elimination half-life,"The mean (+/- SD) terminal elimination half-life is 6.06 +/- 2.02 hr, the mean volume of the central compartment is 0.173 L/kg, and 94.1 +/- 8.0% of the intravenous dose is excreted in the urine.",Kinetics and absolute bioavailability of atenolol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/428185/),h,6.06,25224,DB00335,Atenolol
,428185,volume of the central compartment,"The mean (+/- SD) terminal elimination half-life is 6.06 +/- 2.02 hr, the mean volume of the central compartment is 0.173 L/kg, and 94.1 +/- 8.0% of the intravenous dose is excreted in the urine.",Kinetics and absolute bioavailability of atenolol. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/428185/),[l] / [kg],0.173,25225,DB00335,Atenolol
,428185,plasma clearance,"The mean value of the plasma clearance is 10.7 +/- 1.27 L/hr and of the renal plasma clearance, 10.4 +/- 1.14 L/hr.",Kinetics and absolute bioavailability of atenolol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/428185/),[l] / [h],10.7,25226,DB00335,Atenolol
,428185,renal plasma clearance,"The mean value of the plasma clearance is 10.7 +/- 1.27 L/hr and of the renal plasma clearance, 10.4 +/- 1.14 L/hr.",Kinetics and absolute bioavailability of atenolol. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/428185/),[l] / [h],10.4,25227,DB00335,Atenolol
,428185,absolute bioavailability,"The mean absolute bioavailability for the 25-, 50-, and 100-mg oral doses is 0.52 +/- 0.18, 0.54 +/- 0.12, and 0.58 +/- 0.16, respectively.",Kinetics and absolute bioavailability of atenolol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/428185/),,0.52,25228,DB00335,Atenolol
,428185,absolute bioavailability,"The mean absolute bioavailability for the 25-, 50-, and 100-mg oral doses is 0.52 +/- 0.18, 0.54 +/- 0.12, and 0.58 +/- 0.16, respectively.",Kinetics and absolute bioavailability of atenolol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/428185/),,0.54,25229,DB00335,Atenolol
,428185,absolute bioavailability,"The mean absolute bioavailability for the 25-, 50-, and 100-mg oral doses is 0.52 +/- 0.18, 0.54 +/- 0.12, and 0.58 +/- 0.16, respectively.",Kinetics and absolute bioavailability of atenolol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/428185/),,0.58,25230,DB00335,Atenolol
,428185,Time to mean maximum plasma concentration,Time to mean maximum plasma concentration (3.0 hr) and the time for half of the bioavailable dose to be absorbed (2.0 hr) do not differ significantly with dose.,Kinetics and absolute bioavailability of atenolol. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/428185/),h,3.0,25231,DB00335,Atenolol
,428185,time for half of the bioavailable dose to be absorbed,Time to mean maximum plasma concentration (3.0 hr) and the time for half of the bioavailable dose to be absorbed (2.0 hr) do not differ significantly with dose.,Kinetics and absolute bioavailability of atenolol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/428185/),h,2.0,25232,DB00335,Atenolol
,428185,renal plasma clearance,The mean renal plasma clearance after oral doses (9.49 +/- 1.6 L/hr) is in the same range as renal clearance after intravenous doses.,Kinetics and absolute bioavailability of atenolol. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/428185/),[l] / [h],9.49,25233,DB00335,Atenolol
,973955,half-life,The half-life of atenolol in blood was calculated to ablut 9 hours.,"Human pharmacokinetic and pharmacodynamic studies on the atenolo (ICI 66,082), a new cardioselective beta-adrenoceptor blocking drug. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/973955/),h,9,33107,DB00335,Atenolol
>,24947446,CL,"2. The clearance (CL) values of high CL compounds (CL > 50 mL/min/kg, namely propranolol, diazepam, phenytoin, ethinylestradiol, lorcaserin and fenfluramine) decreased significantly (1.5- to 6-fold) in DIO and AM rats as compared to lean rats, while there was no clear trend for change in CL for the low-to-moderate CL compounds (CL < 50 mL/min/kg, namely atenolol, chlorzoxazone, vancomycin and sibutramine).","Role of hepatic blood flow and metabolism in the pharmacokinetics of ten drugs in lean, aged and obese rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24947446/),[ml] / [kg·min],50,34154,DB00335,Atenolol
<,24947446,CL,"2. The clearance (CL) values of high CL compounds (CL > 50 mL/min/kg, namely propranolol, diazepam, phenytoin, ethinylestradiol, lorcaserin and fenfluramine) decreased significantly (1.5- to 6-fold) in DIO and AM rats as compared to lean rats, while there was no clear trend for change in CL for the low-to-moderate CL compounds (CL < 50 mL/min/kg, namely atenolol, chlorzoxazone, vancomycin and sibutramine).","Role of hepatic blood flow and metabolism in the pharmacokinetics of ten drugs in lean, aged and obese rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24947446/),[ml] / [kg·min],50,34155,DB00335,Atenolol
,21593283,AUC(0-24),"The mean AUC(0-24) of celiprolol was lower in SLCO2B1*3/*3 individuals (775 ng·h/mL) than in *1/*3 (1097 ng·h/mL) and *1/*1 (1547 ng·h/mL) individuals following the TD, and this was confirmed in population pharmacokinetic analysis with statistical significances; however, SLCO2B1 genotype-dependent differences disappeared following the MD.","Microdosing clinical study: pharmacokinetic, pharmacogenomic (SLCO2B1), and interaction (grapefruit juice) profiles of celiprolol following the oral microdose and therapeutic dose. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21593283/),[h·ng] / [ml],775,35046,DB00335,Atenolol
,21593283,AUC(0-24),"The mean AUC(0-24) of celiprolol was lower in SLCO2B1*3/*3 individuals (775 ng·h/mL) than in *1/*3 (1097 ng·h/mL) and *1/*1 (1547 ng·h/mL) individuals following the TD, and this was confirmed in population pharmacokinetic analysis with statistical significances; however, SLCO2B1 genotype-dependent differences disappeared following the MD.","Microdosing clinical study: pharmacokinetic, pharmacogenomic (SLCO2B1), and interaction (grapefruit juice) profiles of celiprolol following the oral microdose and therapeutic dose. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21593283/),[h·ng] / [ml],1097,35047,DB00335,Atenolol
,21593283,AUC(0-24),"The mean AUC(0-24) of celiprolol was lower in SLCO2B1*3/*3 individuals (775 ng·h/mL) than in *1/*3 (1097 ng·h/mL) and *1/*1 (1547 ng·h/mL) individuals following the TD, and this was confirmed in population pharmacokinetic analysis with statistical significances; however, SLCO2B1 genotype-dependent differences disappeared following the MD.","Microdosing clinical study: pharmacokinetic, pharmacogenomic (SLCO2B1), and interaction (grapefruit juice) profiles of celiprolol following the oral microdose and therapeutic dose. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21593283/),[h·ng] / [ml],1547,35048,DB00335,Atenolol
,3323073,flow rate of the mobile phase,The flow rate of the mobile phase was 1.5 ml/min.,Determination of biological equivalence of two atenolol preparations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3323073/),[ml] / [min],1.5,37406,DB00335,Atenolol
,3323073,Biological half-life,"Biological half-life was on the average 3.8 h, absorption half-life 0.8 h, and the peak concentration time 2.5 h.",Determination of biological equivalence of two atenolol preparations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3323073/),h,3.8,37407,DB00335,Atenolol
,3323073,absorption half-life,"Biological half-life was on the average 3.8 h, absorption half-life 0.8 h, and the peak concentration time 2.5 h.",Determination of biological equivalence of two atenolol preparations. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3323073/),h,0.8,37408,DB00335,Atenolol
,3323073,peak concentration time,"Biological half-life was on the average 3.8 h, absorption half-life 0.8 h, and the peak concentration time 2.5 h.",Determination of biological equivalence of two atenolol preparations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3323073/),h,2.5,37409,DB00335,Atenolol
,6487486,clearance,The calculated urinary (n = 4) and peritoneal (n = 7) clearance was 0.289 +/- 0.058 l/h and 0.152 +/- 0.018 l/h respectively.,Atenolol pharmacokinetics in patients on continuous ambulatory peritoneal dialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487486/),[l] / [h],0.289,37595,DB00335,Atenolol
,6487486,clearance,The calculated urinary (n = 4) and peritoneal (n = 7) clearance was 0.289 +/- 0.058 l/h and 0.152 +/- 0.018 l/h respectively.,Atenolol pharmacokinetics in patients on continuous ambulatory peritoneal dialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487486/),[l] / [h],0.152,37596,DB00335,Atenolol
,6487486,total body clearance,This was considerably less than calculated total body clearance (1.21 +/- 0.086 l/h).,Atenolol pharmacokinetics in patients on continuous ambulatory peritoneal dialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487486/),[l] / [h],1.21,37597,DB00335,Atenolol
,2883988,plasma elimination half-life,The plasma elimination half-life was 47.6 +/- 8.1 h.,"The assessment in man of the beta-adrenoceptor blocking activity and cardioselectivity of H-I 42 BS, a long acting beta-adrenoceptor blocking drug. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2883988/),h,47.6,42931,DB00335,Atenolol
,17571567,Cmax,"Some pharmacokinetic parameters of lidocaine were statistically significant higher (p < 0.05, ANOVA) for the rats treated with atenolol compared with control group: Cmax (196.97 +/- 2.15 ng/ml vs. 125.29 +/- 2.90 ng/ml), AUD (7734.07 +/- 129.06 ng/ ml x min vs. 4478.57 +/- 296.61 ng/ml x min), AUC1 after 5 minutes (314.23 +/- 6.59 ng/ml x min vs. 190.71 +/- 19.75 ng/ml x min).",[Research on the effect of atenolol on lidocaine pharmacokinetics in rats]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17571567/),[ng] / [ml],196.97,43563,DB00335,Atenolol
,17571567,Cmax,"Some pharmacokinetic parameters of lidocaine were statistically significant higher (p < 0.05, ANOVA) for the rats treated with atenolol compared with control group: Cmax (196.97 +/- 2.15 ng/ml vs. 125.29 +/- 2.90 ng/ml), AUD (7734.07 +/- 129.06 ng/ ml x min vs. 4478.57 +/- 296.61 ng/ml x min), AUC1 after 5 minutes (314.23 +/- 6.59 ng/ml x min vs. 190.71 +/- 19.75 ng/ml x min).",[Research on the effect of atenolol on lidocaine pharmacokinetics in rats]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17571567/),[ng] / [ml],125.29,43564,DB00335,Atenolol
,17571567,AUD,"Some pharmacokinetic parameters of lidocaine were statistically significant higher (p < 0.05, ANOVA) for the rats treated with atenolol compared with control group: Cmax (196.97 +/- 2.15 ng/ml vs. 125.29 +/- 2.90 ng/ml), AUD (7734.07 +/- 129.06 ng/ ml x min vs. 4478.57 +/- 296.61 ng/ml x min), AUC1 after 5 minutes (314.23 +/- 6.59 ng/ml x min vs. 190.71 +/- 19.75 ng/ml x min).",[Research on the effect of atenolol on lidocaine pharmacokinetics in rats]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17571567/),[ng] / [min·ml],7734.07,43565,DB00335,Atenolol
,17571567,AUD,"Some pharmacokinetic parameters of lidocaine were statistically significant higher (p < 0.05, ANOVA) for the rats treated with atenolol compared with control group: Cmax (196.97 +/- 2.15 ng/ml vs. 125.29 +/- 2.90 ng/ml), AUD (7734.07 +/- 129.06 ng/ ml x min vs. 4478.57 +/- 296.61 ng/ml x min), AUC1 after 5 minutes (314.23 +/- 6.59 ng/ml x min vs. 190.71 +/- 19.75 ng/ml x min).",[Research on the effect of atenolol on lidocaine pharmacokinetics in rats]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17571567/),[ng] / [min·ml],4478.57,43566,DB00335,Atenolol
,17571567,AUC1,"Some pharmacokinetic parameters of lidocaine were statistically significant higher (p < 0.05, ANOVA) for the rats treated with atenolol compared with control group: Cmax (196.97 +/- 2.15 ng/ml vs. 125.29 +/- 2.90 ng/ml), AUD (7734.07 +/- 129.06 ng/ ml x min vs. 4478.57 +/- 296.61 ng/ml x min), AUC1 after 5 minutes (314.23 +/- 6.59 ng/ml x min vs. 190.71 +/- 19.75 ng/ml x min).",[Research on the effect of atenolol on lidocaine pharmacokinetics in rats]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17571567/),[ng] / [min·ml],314.23,43567,DB00335,Atenolol
,17571567,AUC1,"Some pharmacokinetic parameters of lidocaine were statistically significant higher (p < 0.05, ANOVA) for the rats treated with atenolol compared with control group: Cmax (196.97 +/- 2.15 ng/ml vs. 125.29 +/- 2.90 ng/ml), AUD (7734.07 +/- 129.06 ng/ ml x min vs. 4478.57 +/- 296.61 ng/ml x min), AUC1 after 5 minutes (314.23 +/- 6.59 ng/ml x min vs. 190.71 +/- 19.75 ng/ml x min).",[Research on the effect of atenolol on lidocaine pharmacokinetics in rats]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17571567/),[ng] / [min·ml],190.71,43568,DB00335,Atenolol
,17571567,Tmax,"Tmax was 20 minutes, similar for both groups.",[Research on the effect of atenolol on lidocaine pharmacokinetics in rats]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17571567/),min,20,43569,DB00335,Atenolol
,8398605,detection limits,The detection limits of 5 ng/ml enantiomer in plasma and 50 ng/ml enantiomer in urine are sufficient for pharmacokinetic studies after therapeutic doses.,"Direct enantiospecific HPLC bioanalysis of (R,S)-atenolol on a chiral stationary phase. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8398605/),[ng] / [ml],5,46431,DB00335,Atenolol
,8398605,detection limits,The detection limits of 5 ng/ml enantiomer in plasma and 50 ng/ml enantiomer in urine are sufficient for pharmacokinetic studies after therapeutic doses.,"Direct enantiospecific HPLC bioanalysis of (R,S)-atenolol on a chiral stationary phase. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8398605/),[ng] / [ml],50,46432,DB00335,Atenolol
,465278,Bioavailability,Bioavailability of the orally administered atenolol was 50%.,"Pharmacokinetics, pharmacology of atenolol and effect of renal disease. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/465278/),%,50,47010,DB00335,Atenolol
,6148873,half-life,"Twenty-four hours after the dose, the percentage of the maximal heart rate-attenuating effect was highest for nadolol (pharmacokinetic half-life, 15.5 hours), followed by atenolol and then by pindolol (half-life, 5.5 hours).","Atenolol, nadolol, and pindolol in angina pectoris on effort: effect of pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6148873/),h,15.5,47871,DB00335,Atenolol
,6148873,half-life,"Twenty-four hours after the dose, the percentage of the maximal heart rate-attenuating effect was highest for nadolol (pharmacokinetic half-life, 15.5 hours), followed by atenolol and then by pindolol (half-life, 5.5 hours).","Atenolol, nadolol, and pindolol in angina pectoris on effort: effect of pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6148873/),h,5.5,47872,DB00335,Atenolol
,2312778,relative bioavailability,The relative bioavailability of CR/ZOK to CT was 69.0%.,Pharmacokinetic and pharmacodynamic properties of controlled release (CR/ZOK) metoprolol in healthy Oriental subjects: a comparison with conventional formulations of metoprolol and atenolol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2312778/),%,69.0,49766,DB00335,Atenolol
,6111331,maximum effect,The maximum effect (34.4 +/- 2.2%) occurred after 40 mg.,"Observation on the efficacy and pharmacokinetics of betaxolol (SL 75212), a cardioselective beta-adrenoceptor blocking drug. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6111331/),%,34.4,49948,DB00335,Atenolol
,6111331,plasma elimination half-lives,"The plasma elimination half-lives after 10, 20 and 40 mg were 11.4 +/- 2.5, 15.9 +/- 4.9 and 15.1 +/- 3.1 h.","Observation on the efficacy and pharmacokinetics of betaxolol (SL 75212), a cardioselective beta-adrenoceptor blocking drug. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6111331/),h,11.4,49949,DB00335,Atenolol
,6111331,plasma elimination half-lives,"The plasma elimination half-lives after 10, 20 and 40 mg were 11.4 +/- 2.5, 15.9 +/- 4.9 and 15.1 +/- 3.1 h.","Observation on the efficacy and pharmacokinetics of betaxolol (SL 75212), a cardioselective beta-adrenoceptor blocking drug. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6111331/),h,15.9,49950,DB00335,Atenolol
,6111331,plasma elimination half-lives,"The plasma elimination half-lives after 10, 20 and 40 mg were 11.4 +/- 2.5, 15.9 +/- 4.9 and 15.1 +/- 3.1 h.","Observation on the efficacy and pharmacokinetics of betaxolol (SL 75212), a cardioselective beta-adrenoceptor blocking drug. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6111331/),h,15.1,49951,DB00335,Atenolol
,6111331,half-life,The half-life for betaxolol was 24.5 h which was longer than that for any of the other drugs.,"Observation on the efficacy and pharmacokinetics of betaxolol (SL 75212), a cardioselective beta-adrenoceptor blocking drug. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6111331/),h,24.5,49952,DB00335,Atenolol
,7378254,peak plasma level,"2 The peak plasma level, 1.59 +/- 0.43 mg/l, was reached in 4.7 +/- 2.1 h.",Pharmacokinetics of atenolol in patients with terminal renal failure and influence of haemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7378254/),[mg] / [l],1.59,52052,DB00335,Atenolol
,7378254,apparent plasma half-life,"3 Without dialysis treatment, the apparent plasma half-life of atenolol was greatly increased (73.4 +/- 28.8 /).",Pharmacokinetics of atenolol in patients with terminal renal failure and influence of haemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7378254/),-1,73.4,52053,DB00335,Atenolol
,7378254,Renal clearance,4 Renal clearance of atenolol was very low (4.6 +/- 1.5 ml/min).,Pharmacokinetics of atenolol in patients with terminal renal failure and influence of haemodialysis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7378254/),[ml] / [min],4.6,52054,DB00335,Atenolol
,7378254,Plasma clearance,5 Plasma clearance during dialysis was 42.6 +/- 21.3 ml/min for a mean blood flow-rate of 236 +/- 25 ml/min through a cuprophane membrane dialyser.,Pharmacokinetics of atenolol in patients with terminal renal failure and influence of haemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7378254/),[ml] / [min],42.6,52055,DB00335,Atenolol
,7378254,blood flow-rate,5 Plasma clearance during dialysis was 42.6 +/- 21.3 ml/min for a mean blood flow-rate of 236 +/- 25 ml/min through a cuprophane membrane dialyser.,Pharmacokinetics of atenolol in patients with terminal renal failure and influence of haemodialysis. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7378254/),[ml] / [min],236,52056,DB00335,Atenolol
,7236872,time of peaking (tmax),Propantheline prolonged the absorption phase of atenolol and the time of peaking (tmax) was shifted from 2.1 to 4.5 h.,"The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7236872/),h,2.1,56406,DB00335,Atenolol
,7236872,time of peaking (tmax),Propantheline prolonged the absorption phase of atenolol and the time of peaking (tmax) was shifted from 2.1 to 4.5 h.,"The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7236872/),h,4.5,56407,DB00335,Atenolol
,1788167,flow rate,The resulting diastereomers were chromatographed with normal-phase HPLC with chloroform:hexane:methanol [65:33:2 (v/v)] as the mobile phase at a flow rate of 2 ml/min.,Stereospecific high-performance liquid chromatographic assay of sotalol in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1788167/),[ml] / [min],2,58285,DB00335,Atenolol
,24282934,flow rate,"The polar ionic mobile phase consisted of methanol-glacial acetic acidtriethylamine (100 + 0.025 + 0.75, v/v/v) at a flow rate of 0.8 mL/min.",Enantioselective quantification of atenolol in mouse plasma by high performance liquid chromatography using a chiral Stationary phase: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24282934/),[ml] / [min],0.8,60925,DB00335,Atenolol
,24282934,overall recoveries,The overall recoveries for S-(-)- and R-(+)-atenolol enantiomers from plasma were 95.0-99.5%; RSD ranged from 2.5 to 3.3%.,Enantioselective quantification of atenolol in mouse plasma by high performance liquid chromatography using a chiral Stationary phase: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24282934/),%,95.0-99.5,60926,DB00335,Atenolol
,1822203,retention times,"The retention times of atenolol and internal standard, bamethan, are 4.4 and 6.3 min, respectively.",A validated high-performance liquid chromatographic method for the determination of atenolol in whole blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1822203/),min,4.4,62024,DB00335,Atenolol
,1822203,retention times,"The retention times of atenolol and internal standard, bamethan, are 4.4 and 6.3 min, respectively.",A validated high-performance liquid chromatographic method for the determination of atenolol in whole blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1822203/),min,6.3,62025,DB00335,Atenolol
,1822203,absolute recovery,The mean absolute recovery of atenolol using the described assay is 90%.,A validated high-performance liquid chromatographic method for the determination of atenolol in whole blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1822203/),%,90,62026,DB00335,Atenolol
,32816,maximal plasma concentration,"After administration of a dose of 200 mg by the oral route to hypertensive subjects, one may observe a maximal plasma concentration 3 hours after the dose average value 3.91 +/- 0.71 mumol/l (1.04 +/- 0.19 mg/l).",[Spectrofluorimetric estimation in biological fluids of a new beta-blockader: atenolol. Application to its pharmacokinetic study (author's transl)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32816/),[μM] / [l],3.91,64507,DB00335,Atenolol
,32816,maximal plasma concentration,"After administration of a dose of 200 mg by the oral route to hypertensive subjects, one may observe a maximal plasma concentration 3 hours after the dose average value 3.91 +/- 0.71 mumol/l (1.04 +/- 0.19 mg/l).",[Spectrofluorimetric estimation in biological fluids of a new beta-blockader: atenolol. Application to its pharmacokinetic study (author's transl)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32816/),[mg] / [l],1.04,64508,DB00335,Atenolol
,32816,apparent half life of elimination of phase beta,"The apparent half life of elimination of phase beta is 14.1 +/- 4.9 h, values comparable with those calculated from urinary data 14.6 +/- 2.0 h.",[Spectrofluorimetric estimation in biological fluids of a new beta-blockader: atenolol. Application to its pharmacokinetic study (author's transl)]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32816/),h,14.1,64509,DB00335,Atenolol
,32816,apparent half life of elimination of phase beta,"The apparent half life of elimination of phase beta is 14.1 +/- 4.9 h, values comparable with those calculated from urinary data 14.6 +/- 2.0 h.",[Spectrofluorimetric estimation in biological fluids of a new beta-blockader: atenolol. Application to its pharmacokinetic study (author's transl)]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32816/),h,14.6,64510,DB00335,Atenolol
,32816,renal clearance,The renal clearance was 140 +/- 32 ml/min; 54 +/- 14% of the administered dose are excreted in the urine.,[Spectrofluorimetric estimation in biological fluids of a new beta-blockader: atenolol. Application to its pharmacokinetic study (author's transl)]. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32816/),[ml] / [min],140,64511,DB00335,Atenolol
,7363534,half-life,"During haemodialysis, however, its concentration decreases with a half-life of 5h.",The pharmacokinetics of metoprolol and its metabolites in dialysis patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7363534/),h,5,65125,DB00335,Atenolol
,6243518,elimination half-life,"Serum levels rose linearly, with an average elimination half-life of about 10 hours after chronic oral dosing.",Atenolol: once-daily cardioselective beta blockade for angina pectoris. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6243518/),h,10,77502,DB00335,Atenolol
,2903820,oral bioavailability,"The oral bioavailability of bisoprolol is high (90%) and the drug has a long elimination half-life which allows once-daily administration; in addition, it is hepatically and renally cleared in equal proportions.","Bisoprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2903820/),%,90,81252,DB00335,Atenolol
,7202470,peak plasma concentration,After a 50 mg oral dose mean (+/- SD) peak plasma concentration of T was 1.13 +/- 0.29 micrograms/ml-1 and occurred 0.79 +/- 0.40 h after the dose; mean peak plasma concentration of its sulphone metabolite (M) was 0.37 +/- 0.09 micrograms/ml-1 at 1.92 +/- 1.32 h after the dose.,A clinical and pharmacokinetic evaluation of tolmesoxide in hypertensive patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7202470/),[μg] / [ml],1.13,84052,DB00335,Atenolol
,7202470,peak plasma concentration,After a 50 mg oral dose mean (+/- SD) peak plasma concentration of T was 1.13 +/- 0.29 micrograms/ml-1 and occurred 0.79 +/- 0.40 h after the dose; mean peak plasma concentration of its sulphone metabolite (M) was 0.37 +/- 0.09 micrograms/ml-1 at 1.92 +/- 1.32 h after the dose.,A clinical and pharmacokinetic evaluation of tolmesoxide in hypertensive patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7202470/),[μg] / [ml],0.37,84053,DB00335,Atenolol
,7202470,half-lives,Following peak plasma concentrations there was a monoexponential decline in T and M concentrations with half-lives of 2.78 +/- 0.77 h and 10.78 +/- 7.85 h respectively.,A clinical and pharmacokinetic evaluation of tolmesoxide in hypertensive patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7202470/),h,2.78,84054,DB00335,Atenolol
,7202470,half-lives,Following peak plasma concentrations there was a monoexponential decline in T and M concentrations with half-lives of 2.78 +/- 0.77 h and 10.78 +/- 7.85 h respectively.,A clinical and pharmacokinetic evaluation of tolmesoxide in hypertensive patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7202470/),h,10.78,84055,DB00335,Atenolol
,7202470,pulse rate,Supine pulse rate increased (mean +/- SD) significantly from 55 +/- 5/min to 66 +/- 8/min following 900--1500 mg T in 4 out-patients.,A clinical and pharmacokinetic evaluation of tolmesoxide in hypertensive patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7202470/),1/[min],55,84056,DB00335,Atenolol
,7202470,pulse rate,Supine pulse rate increased (mean +/- SD) significantly from 55 +/- 5/min to 66 +/- 8/min following 900--1500 mg T in 4 out-patients.,A clinical and pharmacokinetic evaluation of tolmesoxide in hypertensive patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7202470/),1/[min],66,84057,DB00335,Atenolol
,8941022,hepatic extraction,The mean hepatic extraction of fluvastatin was 67% after the jejunal perfusion and 73% after the intravenous infusion.,Jejunal permeability and hepatic extraction of fluvastatin in humans. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8941022/),%,67,88754,DB00335,Atenolol
,8941022,hepatic extraction,The mean hepatic extraction of fluvastatin was 67% after the jejunal perfusion and 73% after the intravenous infusion.,Jejunal permeability and hepatic extraction of fluvastatin in humans. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8941022/),%,73,88755,DB00335,Atenolol
,8941022,half-life,The half-life of fluvastatin was approximately 60 minutes after both administration routes.,Jejunal permeability and hepatic extraction of fluvastatin in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8941022/),min,60,88756,DB00335,Atenolol
,23061481,B/P ratio,"Atenolol, a non P-gp substrate, exhibited poor brain penetration in the presence or absence of elacridar in both species (B/P ratio ~ 0.1).",A simplified protocol employing elacridar in rodents: a screening model in drug discovery to assess P-gp mediated efflux at the blood brain barrier. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23061481/),,0.1,89418,DB00335,Atenolol
,2702798,peak concentration,In each subject the peak concentration of d-atenolol was greater than the peak concentration of l-atenolol (mean +/- SD of 420 +/- 81 ng/ml vs 366 +/- 61 ng/ml; p less than 0.05).,The pharmacokinetics of the enantiomers of atenolol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702798/),[ng] / [ml],420,91061,DB00335,Atenolol
,2702798,peak concentration,In each subject the peak concentration of d-atenolol was greater than the peak concentration of l-atenolol (mean +/- SD of 420 +/- 81 ng/ml vs 366 +/- 61 ng/ml; p less than 0.05).,The pharmacokinetics of the enantiomers of atenolol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702798/),[ng] / [ml],366,91062,DB00335,Atenolol
,2702798,renal clearances,"The renal clearances of d- and l-atenolol were not significantly different (109.7 +/- 33.5 ml/min vs 112.5 +/- 36.7 ml/min), probably because the major route of renal elimination is glomerular filtration.",The pharmacokinetics of the enantiomers of atenolol. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702798/),[ml] / [min],109.7,91063,DB00335,Atenolol
,2702798,renal clearances,"The renal clearances of d- and l-atenolol were not significantly different (109.7 +/- 33.5 ml/min vs 112.5 +/- 36.7 ml/min), probably because the major route of renal elimination is glomerular filtration.",The pharmacokinetics of the enantiomers of atenolol. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702798/),[ml] / [min],112.5,91064,DB00335,Atenolol
,2702798,half-lives,The half-lives of d- and l-atenolol were not significantly different (mean +/- SD of 4.6 +/- 1.1 hours vs 5.2 +/- 0.9 hours).,The pharmacokinetics of the enantiomers of atenolol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702798/),h,4.6,91065,DB00335,Atenolol
,2702798,half-lives,The half-lives of d- and l-atenolol were not significantly different (mean +/- SD of 4.6 +/- 1.1 hours vs 5.2 +/- 0.9 hours).,The pharmacokinetics of the enantiomers of atenolol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702798/),h,5.2,91066,DB00335,Atenolol
,12852442,absorption half-life,"The absorption half-life of the investigated drugs ranged from 2 to 59 min, and the extent of absorption from 21 to 94% in 2 h in the isolated perfused rat lung model.",Drug absorption from the isolated perfused rat lung--correlations with drug physicochemical properties and epithelial permeability. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12852442/),min,2 to 59,102577,DB00335,Atenolol
,8240927,R/S ratios,The R/S ratios were 1.09 for AUC(R)/AUC(S) and 1.03 for Cmax (R)/Cmax(S) (P < 0.01) respectively after administration of the racemic drug.,Stereoselective HPLC bioanalysis of atenolol enantiomers in plasma: application to a comparative human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8240927/),,1,102696,DB00335,Atenolol
,520399,time to reach peak concentration,"Food intake significantly shortened the time to reach peak concentration (2.7 h vs 1.5 h), but caused a significant reduction in AUC values, the mean decrease being 20%.",Food-induced reduction in bioavailability of atenolol. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/520399/),h,2.7,106126,DB00335,Atenolol
,520399,time to reach peak concentration,"Food intake significantly shortened the time to reach peak concentration (2.7 h vs 1.5 h), but caused a significant reduction in AUC values, the mean decrease being 20%.",Food-induced reduction in bioavailability of atenolol. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/520399/),h,1.5,106127,DB00335,Atenolol
,29870669,Tmax,Peak milk concentrations of atenolol were observed in the women at 4 hr (Tmax) after oral administration.,Estimation of Atenolol Transfer Into Milk and Infant Exposure During Its Use in Lactating Women. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29870669/),h,4,109315,DB00335,Atenolol
,29870669,milk-to-plasma ratio,The mean milk-to-plasma ratio of the patients who were taking 25 to 100 mg of atenolol was 8.57%.,Estimation of Atenolol Transfer Into Milk and Infant Exposure During Its Use in Lactating Women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29870669/),%,8.57,109316,DB00335,Atenolol
,16628137,flow rate,"Separation was performed on a C18 reverse-phase column (4 microm) using a binary mobile phase consisting of 0.05 M of phosphate buffer, pH 5.5, and methanol (80:20, vol/vol) at a flow rate of 0.7 mL/minute.",A micromethod for the quantification of atenolol in plasma using high-performance liquid chromatography with fluorescence detection: therapeutic drug monitoring of two patients with severe coronary insufficiency before cardiac surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628137/),[ml] / [min],0.7,109634,DB00335,Atenolol
,16628137,retention times,"The retention times of atenolol and of the internal standard (sotalol) were 12.7 and 10.4 minutes, respectively.",A micromethod for the quantification of atenolol in plasma using high-performance liquid chromatography with fluorescence detection: therapeutic drug monitoring of two patients with severe coronary insufficiency before cardiac surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628137/),min,12.7,109635,DB00335,Atenolol
,16628137,retention times,"The retention times of atenolol and of the internal standard (sotalol) were 12.7 and 10.4 minutes, respectively.",A micromethod for the quantification of atenolol in plasma using high-performance liquid chromatography with fluorescence detection: therapeutic drug monitoring of two patients with severe coronary insufficiency before cardiac surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628137/),min,10.4,109636,DB00335,Atenolol
,16628137,Absolute recovery,Absolute recovery was 93.7%.,A micromethod for the quantification of atenolol in plasma using high-performance liquid chromatography with fluorescence detection: therapeutic drug monitoring of two patients with severe coronary insufficiency before cardiac surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628137/),%,93.7,109637,DB00335,Atenolol
,3358894,half-life,The half-life in the elderly was significantly longer (8.8 +/- 0.9 h) compared with that in the young (5.8 +/- 1.1 h) (P less than 0.01).,The effect of ageing on the disposition of nifedipine and atenolol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358894/),h,8.8,111099,DB00335,Atenolol
,3358894,half-life,The half-life in the elderly was significantly longer (8.8 +/- 0.9 h) compared with that in the young (5.8 +/- 1.1 h) (P less than 0.01).,The effect of ageing on the disposition of nifedipine and atenolol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358894/),h,5.8,111100,DB00335,Atenolol
,15359582,systemic clearance,"Testosterone BA was less than 10% by ID, IC, and IPV routes, due to high hepatic extraction, consistent with its high systemic clearance (63 ml x min(-1) x kg(-1)) and short terminal plasma half-life (23 min).",Evaluating barriers to bioavailability in vivo: validation of a technique for separately assessing gastrointestinal absorption and hepatic extraction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15359582/),[ml] / [kg·min],63,112742,DB00335,Atenolol
,15359582,terminal plasma half-life,"Testosterone BA was less than 10% by ID, IC, and IPV routes, due to high hepatic extraction, consistent with its high systemic clearance (63 ml x min(-1) x kg(-1)) and short terminal plasma half-life (23 min).",Evaluating barriers to bioavailability in vivo: validation of a technique for separately assessing gastrointestinal absorption and hepatic extraction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15359582/),min,23,112743,DB00335,Atenolol
,15359582,BA,"The IPV BA of amoxicillin was 95%+/-6% indicating the absence of hepatic extraction in the rat, but with an ID BA of approximately 39% suggesting incomplete GI absorption to be the main barrier to bioavailability.",Evaluating barriers to bioavailability in vivo: validation of a technique for separately assessing gastrointestinal absorption and hepatic extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15359582/),%,95,112744,DB00335,Atenolol
,15359582,BA,"The IPV BA of amoxicillin was 95%+/-6% indicating the absence of hepatic extraction in the rat, but with an ID BA of approximately 39% suggesting incomplete GI absorption to be the main barrier to bioavailability.",Evaluating barriers to bioavailability in vivo: validation of a technique for separately assessing gastrointestinal absorption and hepatic extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15359582/),%,39,112745,DB00335,Atenolol
,15359582,BA,Low oral BA of propranolol was due in part to first-pass hepatic extraction (IPV BA of 36%).,Evaluating barriers to bioavailability in vivo: validation of a technique for separately assessing gastrointestinal absorption and hepatic extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15359582/),%,36,112746,DB00335,Atenolol
,1806626,elimination half-life,The elimination half-life is about 32 h; metabolism is by demethylation to an inactive metabolite.,Clinical implications of the pharmacology of sertraline. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1806626/),h,32,117841,DB00335,Atenolol
,2859047,peak levels of radioactivity,"In three subjects given 10 mg of [14C]-Ro31-1118 orally, peak levels of radioactivity (84 +/- 5 ng/ml) were 16 times those of the parent drug (approximately 5 ng/ml).","Human pharmacokinetic and pharmacodynamic studies on Ro31-1118, a new beta-adrenoceptor antagonist. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2859047/),[ng] / [ml],84,118816,DB00335,Atenolol
,2859047,peak levels of radioactivity,"In three subjects given 10 mg of [14C]-Ro31-1118 orally, peak levels of radioactivity (84 +/- 5 ng/ml) were 16 times those of the parent drug (approximately 5 ng/ml).","Human pharmacokinetic and pharmacodynamic studies on Ro31-1118, a new beta-adrenoceptor antagonist. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2859047/),[ng] / [ml],5,118817,DB00335,Atenolol
,2859047,recovery,"Very little parent drug was recovered in the urine, although recovery of total radioactivity was nearly 80% in the urine by day 5.","Human pharmacokinetic and pharmacodynamic studies on Ro31-1118, a new beta-adrenoceptor antagonist. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2859047/),%,80,118818,DB00335,Atenolol
,2859047,bioavailability,In five subjects studied after both oral and intravenous administration of 20 mg Ro31-1118 the average bioavailability was 57% (range 41-73%).,"Human pharmacokinetic and pharmacodynamic studies on Ro31-1118, a new beta-adrenoceptor antagonist. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2859047/),%,57,118819,DB00335,Atenolol
,2859047,apparent volume of distribution,Following intravenous infusion the apparent volume of distribution for the five subjects averaged 590 1 (range 510-700 1).,"Human pharmacokinetic and pharmacodynamic studies on Ro31-1118, a new beta-adrenoceptor antagonist. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2859047/),1,590,118820,DB00335,Atenolol
,2859047,elimination half-life,The elimination half-life averaged 18 h (range 17-26 h).,"Human pharmacokinetic and pharmacodynamic studies on Ro31-1118, a new beta-adrenoceptor antagonist. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2859047/),h,18,118821,DB00335,Atenolol
,7408390,half-life (t1/2),The blood atenolol half-life (t1/2) increased from about 6 hr to more than 100 hr with progressive renal failure and there was a corresponding decrease in elimination rate constant and increase in area under the curve.,Atenolol kinetics in renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7408390/),h,6,119794,DB00335,Atenolol
,7408390,half-life (t1/2),The blood atenolol half-life (t1/2) increased from about 6 hr to more than 100 hr with progressive renal failure and there was a corresponding decrease in elimination rate constant and increase in area under the curve.,Atenolol kinetics in renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7408390/),h,more,119795,DB00335,Atenolol
,7408390,half-life (t1/2),The blood atenolol half-life (t1/2) increased from about 6 hr to more than 100 hr with progressive renal failure and there was a corresponding decrease in elimination rate constant and increase in area under the curve.,Atenolol kinetics in renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7408390/),h,100,119796,DB00335,Atenolol
,2939868,half-life,"Pharmacokinetics of doxazosin, measured at steady state in 36 patients, showed dose-related plasma concentrations, a mean half-life of about 12 h and relatively low intersubject variation.",A long-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate essential hypertension. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2939868/),h,12,120031,DB00335,Atenolol
,6863581,plasma half-life,"Thus, plasma half-life after intravenous dosing of atenolol was 6.0 +/- 0.46 hours in patients with hepatic disease and 5.0 +/- 0.4 hours in the controls, indicating absence of atenolol accumulation in hepatic failure.",Clinical experience with atenolol in patients with chronic liver disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6863581/),h,6.0,121625,DB00335,Atenolol
,6863581,plasma half-life,"Thus, plasma half-life after intravenous dosing of atenolol was 6.0 +/- 0.46 hours in patients with hepatic disease and 5.0 +/- 0.4 hours in the controls, indicating absence of atenolol accumulation in hepatic failure.",Clinical experience with atenolol in patients with chronic liver disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6863581/),h,5.0,121626,DB00335,Atenolol
,6825385,bioavailability,"After a single oral dose of 100 mg atenolol combined with 1 gm ampicillin, the bioavailability of atenolol was reduced to 36 +/- 5% compared to 60 +/- 8% after monotherapy.","Atenolol interaction with aspirin, allopurinol, and ampicillin. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6825385/),%,36,126959,DB00335,Atenolol
,6825385,bioavailability,"After a single oral dose of 100 mg atenolol combined with 1 gm ampicillin, the bioavailability of atenolol was reduced to 36 +/- 5% compared to 60 +/- 8% after monotherapy.","Atenolol interaction with aspirin, allopurinol, and ampicillin. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6825385/),%,60,126960,DB00335,Atenolol
,6825385,bioavailability,During long-term treatment with atenolol and ampicillin the bioavailability of atenolol fell to 24% (P less than 0.01).,"Atenolol interaction with aspirin, allopurinol, and ampicillin. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6825385/),%,24,126961,DB00335,Atenolol
,6825385,peak plasma levels,Mean peak plasma levels were lowered from 511 +/- 59 ng/ml on monotherapy to 344 +/- 33 ng/ml after the combination with ampicillin.,"Atenolol interaction with aspirin, allopurinol, and ampicillin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6825385/),[ng] / [ml],511,126962,DB00335,Atenolol
,6825385,peak plasma levels,Mean peak plasma levels were lowered from 511 +/- 59 ng/ml on monotherapy to 344 +/- 33 ng/ml after the combination with ampicillin.,"Atenolol interaction with aspirin, allopurinol, and ampicillin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6825385/),[ng] / [ml],344,126963,DB00335,Atenolol
,658112,bioavailability,The bioavailability of approximately 50% is due to reduced absorption.,Studies on the pharmacokinetics and pharmacodynamics of atenolol in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/658112/),%,50,129449,DB00335,Atenolol
,658112,half life,Peak blood levels are observed at 2-4 h and the half life of atenolol given orally is 5-6 h.,Studies on the pharmacokinetics and pharmacodynamics of atenolol in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/658112/),h,5-6,129450,DB00335,Atenolol
,7332738,plasma half-life,2 The pharmacokinetics of atenolol (plasma half-life of about 8 h) in pregnant women do not differ from the findings in the non-pregnant.,Atenolol in the treatment of pregnancy-induced hypertension. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7332738/),h,8,130916,DB00335,Atenolol
,13958,t1/2 of distribution,The t1/2 of distribution ranges between 5 to 30 minutes.,Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13958/),min,5 to 30,131024,DB00335,Atenolol
,13958,elimination half-life,The beta-blockers are relatively rapidly eliminated from the body and most of them have an elimination half-life between 2 to 4 hours.,Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/13958/),h,2 to 4,131025,DB00335,Atenolol
,17090396,skin permeation,The product which shows in vitro drug skin permeation near to 64 mcg/h/ml was selected for in vivo studies.,Transdermal atenolol releasing system: an approach towards its development. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17090396/),[mcg] / [h·ml],64,131350,DB00335,Atenolol
,17090396,AUC0-28,The AUC0-28 with Ma EC HPMC 46 was better than orally administered conventional doses at twelve hours interval (AUC0-28 1587 ng h/ml) as well as no trough and peaks in drug plasma level was recorded with TDDS.,Transdermal atenolol releasing system: an approach towards its development. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17090396/),[h·ng] / [ml],1587,131351,DB00335,Atenolol
,6839004,renal clearance,"In contrast, mean peak plasma levels and AUC for atenolol were significantly lower, both by about 40 per cent, during infectious disease compared to the healthy state (p less than 0.05), where as renal clearance of atenolol slightly increased from 110.8 +/- 14.7 ml min-1 in the healthy state to 128 +/- 21.6 ml min-1, when the ESR's were elevated.",Influence of inflammatory disease on the clinical pharmacokinetics of atenolol and metoprolol. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6839004/),[ml] / [min],110.8,133340,DB00335,Atenolol
,6839004,renal clearance,"In contrast, mean peak plasma levels and AUC for atenolol were significantly lower, both by about 40 per cent, during infectious disease compared to the healthy state (p less than 0.05), where as renal clearance of atenolol slightly increased from 110.8 +/- 14.7 ml min-1 in the healthy state to 128 +/- 21.6 ml min-1, when the ESR's were elevated.",Influence of inflammatory disease on the clinical pharmacokinetics of atenolol and metoprolol. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6839004/),[ml] / [min],128,133341,DB00335,Atenolol
,6839004,elimination half-life,"The elimination half-life of atenolol, about 10 h, was not affected by the health status of the subjects.",Influence of inflammatory disease on the clinical pharmacokinetics of atenolol and metoprolol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6839004/),h,10,133342,DB00335,Atenolol
,2904825,elimination half-life,"3. Examination of the pharmacokinetic data showed that bisoprolol had a median elimination half-life of 11.2 h during chronic dosing, compared with 6.4 h for atenolol.",A comparison of bisoprolol and atenolol in the treatment of mild to moderate hypertension. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2904825/),h,11.2,135147,DB00335,Atenolol
,2904825,elimination half-life,"3. Examination of the pharmacokinetic data showed that bisoprolol had a median elimination half-life of 11.2 h during chronic dosing, compared with 6.4 h for atenolol.",A comparison of bisoprolol and atenolol in the treatment of mild to moderate hypertension. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2904825/),h,6.4,135148,DB00335,Atenolol
,2904825,clearance,"For bisoprolol, the median clearance fell from 264 ml min-1 after a single dose to 212 ml min-1 during chronic dosing, although clinically significant accumulation would not be expected during chronic administration.",A comparison of bisoprolol and atenolol in the treatment of mild to moderate hypertension. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2904825/),[ml] / [min],264,135149,DB00335,Atenolol
,2904825,clearance,"For bisoprolol, the median clearance fell from 264 ml min-1 after a single dose to 212 ml min-1 during chronic dosing, although clinically significant accumulation would not be expected during chronic administration.",A comparison of bisoprolol and atenolol in the treatment of mild to moderate hypertension. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2904825/),[ml] / [min],212,135150,DB00335,Atenolol
,17763375,t(1/2),Atenolol aspirinate was stable towards aqueous hydrolysis but rapidly hydrolyzed in plasma (t(1/2) = 7.6 min).,Pharmacokinetic profile of atenolol aspirinate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17763375/),min,7.6,140392,DB00335,Atenolol
,2429095,Maximum plasma concentrations,Maximum plasma concentrations of nifedipine (37.1 +/- 16.7 ng/ml) and atenolol (276.3 +/- 107.2 ng/ml) and terminal half-life of atenolol (9.9 +/- 2.6 h) were not altered by combined administration of the drugs.,Interaction between nifedipine and atenolol: pharmacokinetics and pharmacodynamics in normotensive volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2429095/),[ng] / [ml],37.1,141143,DB00335,Atenolol
,2429095,Maximum plasma concentrations,Maximum plasma concentrations of nifedipine (37.1 +/- 16.7 ng/ml) and atenolol (276.3 +/- 107.2 ng/ml) and terminal half-life of atenolol (9.9 +/- 2.6 h) were not altered by combined administration of the drugs.,Interaction between nifedipine and atenolol: pharmacokinetics and pharmacodynamics in normotensive volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2429095/),[ng] / [ml],276.3,141144,DB00335,Atenolol
,2429095,terminal half-life,Maximum plasma concentrations of nifedipine (37.1 +/- 16.7 ng/ml) and atenolol (276.3 +/- 107.2 ng/ml) and terminal half-life of atenolol (9.9 +/- 2.6 h) were not altered by combined administration of the drugs.,Interaction between nifedipine and atenolol: pharmacokinetics and pharmacodynamics in normotensive volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2429095/),h,9.9,141145,DB00335,Atenolol
,7248478,half-lives,The half-lives were between 5 and 6 h in agreement with other published data.,Bioavailability in man of atenolol and chlorthalidone from a combination formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7248478/),h,5 and 6,144021,DB00335,Atenolol
,7248478,half-lives,The half-lives of all three formulations were similar at about 60 h.,Bioavailability in man of atenolol and chlorthalidone from a combination formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7248478/),h,60,144022,DB00335,Atenolol
,18167085,peak concentration,"2 hours after oral administration, 6 of 7 cats reached therapeutic plasma atenolol concentrations with a mean peak concentration of 579 +/- 212 ng/mL.",Comparison of pharmacodynamic variables following oral versus transdermal administration of atenolol to healthy cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18167085/),[ng] / [ml],579,145927,DB00335,Atenolol
,18167085,peak concentration,"Two hours following transdermal administration, only 2 of 7 cats reached therapeutic plasma atenolol concentrations with a mean peak concentration of 177 +/- 123 ng/mL.",Comparison of pharmacodynamic variables following oral versus transdermal administration of atenolol to healthy cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18167085/),[ng] / [ml],177,145928,DB00335,Atenolol
,18167085,Trough plasma atenolol concentrations,"Trough plasma atenolol concentrations of 258 +/- 142 ng/mL and 62.4 +/- 17 ng/mL were achieved 12 hours after oral and transdermal administration, respectively.",Comparison of pharmacodynamic variables following oral versus transdermal administration of atenolol to healthy cats. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18167085/),[ng] / [ml],258,145929,DB00335,Atenolol
,18167085,Trough plasma atenolol concentrations,"Trough plasma atenolol concentrations of 258 +/- 142 ng/mL and 62.4 +/- 17 ng/mL were achieved 12 hours after oral and transdermal administration, respectively.",Comparison of pharmacodynamic variables following oral versus transdermal administration of atenolol to healthy cats. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18167085/),[ng] / [ml],62.4,145930,DB00335,Atenolol
,28034694,clearance,"When compared to the single cannulation approach, clearance, volume of distribution and bioavailability determined by dual cannulation were 39%, 60% and 38% higher for itraconazole, and 46%, 34% and 42% higher for amiodarone, respectively.",Single jugular vein cannulated rats may not be suitable for intravenous pharmacokinetic screening of high logP compounds. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28034694/),%,39,151866,DB00335,Atenolol
,28034694,volume of distribution,"When compared to the single cannulation approach, clearance, volume of distribution and bioavailability determined by dual cannulation were 39%, 60% and 38% higher for itraconazole, and 46%, 34% and 42% higher for amiodarone, respectively.",Single jugular vein cannulated rats may not be suitable for intravenous pharmacokinetic screening of high logP compounds. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28034694/),%,60,151867,DB00335,Atenolol
,28034694,volume of distribution,"When compared to the single cannulation approach, clearance, volume of distribution and bioavailability determined by dual cannulation were 39%, 60% and 38% higher for itraconazole, and 46%, 34% and 42% higher for amiodarone, respectively.",Single jugular vein cannulated rats may not be suitable for intravenous pharmacokinetic screening of high logP compounds. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28034694/),%,46,151868,DB00335,Atenolol
,28034694,bioavailability,"When compared to the single cannulation approach, clearance, volume of distribution and bioavailability determined by dual cannulation were 39%, 60% and 38% higher for itraconazole, and 46%, 34% and 42% higher for amiodarone, respectively.",Single jugular vein cannulated rats may not be suitable for intravenous pharmacokinetic screening of high logP compounds. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28034694/),%,38,151869,DB00335,Atenolol
,18196225,heart rate nadir,"The daytime mean heart rate nadir was 15% lower when fingolimod was combined with atenolol (42 +/- 7 bpm) compared with fingolimod alone (51 +/- 9 bpm) yielding a combination/monotherapy ratio of 0.85 (90%CI, 0.79-0.92).",The effect on heart rate of combining single-dose fingolimod with steady-state atenolol or diltiazem in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18196225/),bpm,42,153037,DB00335,Atenolol
,18196225,heart rate nadir,"The daytime mean heart rate nadir was 15% lower when fingolimod was combined with atenolol (42 +/- 7 bpm) compared with fingolimod alone (51 +/- 9 bpm) yielding a combination/monotherapy ratio of 0.85 (90%CI, 0.79-0.92).",The effect on heart rate of combining single-dose fingolimod with steady-state atenolol or diltiazem in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18196225/),bpm,51,153038,DB00335,Atenolol
,18196225,heart rate nadir,The daytime mean heart rate nadir from fingolimod alone (55 +/- 5 bpm) was not altered when combined with diltiazem (56 +/- 8 bpm) yielding a ratio of 0.99 (0.94-1.05).,The effect on heart rate of combining single-dose fingolimod with steady-state atenolol or diltiazem in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18196225/),bpm,55,153039,DB00335,Atenolol
,18196225,heart rate nadir,The daytime mean heart rate nadir from fingolimod alone (55 +/- 5 bpm) was not altered when combined with diltiazem (56 +/- 8 bpm) yielding a ratio of 0.99 (0.94-1.05).,The effect on heart rate of combining single-dose fingolimod with steady-state atenolol or diltiazem in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18196225/),bpm,56,153040,DB00335,Atenolol
,2598566,total body clearance,"The intravenous pharmacokinetic data were best described by a two-compartment model and revealed the following (mean +/- SD): total body clearance, 0.15 +/- 0.06 L/hr/kg; volume of the central compartment 0.33 +/- 0.06 L/kg; volume of distribution at steady state, 0.83 +/- 0.15 L/kg; distributive elimination half-life, 0.29 +/- 0.08 hour; and terminal elimination half-life, 4.56 +/- 1.05 hours.",Pharmacokinetics and pharmacodynamics of atenolol in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598566/),[l] / [h·kg],0.15,157199,DB00335,Atenolol
,2598566,volume of the central compartment,"The intravenous pharmacokinetic data were best described by a two-compartment model and revealed the following (mean +/- SD): total body clearance, 0.15 +/- 0.06 L/hr/kg; volume of the central compartment 0.33 +/- 0.06 L/kg; volume of distribution at steady state, 0.83 +/- 0.15 L/kg; distributive elimination half-life, 0.29 +/- 0.08 hour; and terminal elimination half-life, 4.56 +/- 1.05 hours.",Pharmacokinetics and pharmacodynamics of atenolol in children. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598566/),[l] / [kg],0.33,157200,DB00335,Atenolol
,2598566,volume of distribution at steady state,"The intravenous pharmacokinetic data were best described by a two-compartment model and revealed the following (mean +/- SD): total body clearance, 0.15 +/- 0.06 L/hr/kg; volume of the central compartment 0.33 +/- 0.06 L/kg; volume of distribution at steady state, 0.83 +/- 0.15 L/kg; distributive elimination half-life, 0.29 +/- 0.08 hour; and terminal elimination half-life, 4.56 +/- 1.05 hours.",Pharmacokinetics and pharmacodynamics of atenolol in children. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598566/),[l] / [kg],0.83,157201,DB00335,Atenolol
,2598566,elimination half-life,"The intravenous pharmacokinetic data were best described by a two-compartment model and revealed the following (mean +/- SD): total body clearance, 0.15 +/- 0.06 L/hr/kg; volume of the central compartment 0.33 +/- 0.06 L/kg; volume of distribution at steady state, 0.83 +/- 0.15 L/kg; distributive elimination half-life, 0.29 +/- 0.08 hour; and terminal elimination half-life, 4.56 +/- 1.05 hours.",Pharmacokinetics and pharmacodynamics of atenolol in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598566/),h,0.29,157202,DB00335,Atenolol
,2598566,terminal elimination half-life,"The intravenous pharmacokinetic data were best described by a two-compartment model and revealed the following (mean +/- SD): total body clearance, 0.15 +/- 0.06 L/hr/kg; volume of the central compartment 0.33 +/- 0.06 L/kg; volume of distribution at steady state, 0.83 +/- 0.15 L/kg; distributive elimination half-life, 0.29 +/- 0.08 hour; and terminal elimination half-life, 4.56 +/- 1.05 hours.",Pharmacokinetics and pharmacodynamics of atenolol in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598566/),h,4.56,157203,DB00335,Atenolol
,10657059,flow rate,"R,S-sotalol and its internal standard (atenolol) were eluted after 5.9 and 8.5 min, respectively, from a 4-micron C18 reverse-phase column using a mobile phase consisting of 80 mM KH2PO4, pH 4.6, and acetonitrile (95:5, v/v) at a flow rate of 0.5 ml/min with detection at lambdaex = 235 nm and lambdaem = 310 nm, respectively.","A simple HPLC-fluorescence method for the measurement of R,S-sotalol in the plasma of patients with life-threatening cardiac arrhythmias. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10657059/),[ml] / [min],0.5,161467,DB00335,Atenolol
,10657059,C MAX,"Data obtained, expressed as mean, were: C MAX = 1230 ng/ml, T MAX = 1.8 h, AUC T = 10645 ng h-1 ml-1, Kab = 1.23 h-1, alpha = 0.95 h-1, ss = 0.09 h-1, t((1/2))ss = 7.8 h, ClT/F = 3.94 ml min-1 kg-1, and Vd/F = 2.53 l/kg.","A simple HPLC-fluorescence method for the measurement of R,S-sotalol in the plasma of patients with life-threatening cardiac arrhythmias. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10657059/),[ng] / [ml],1230,161468,DB00335,Atenolol
,10657059,T MAX,"Data obtained, expressed as mean, were: C MAX = 1230 ng/ml, T MAX = 1.8 h, AUC T = 10645 ng h-1 ml-1, Kab = 1.23 h-1, alpha = 0.95 h-1, ss = 0.09 h-1, t((1/2))ss = 7.8 h, ClT/F = 3.94 ml min-1 kg-1, and Vd/F = 2.53 l/kg.","A simple HPLC-fluorescence method for the measurement of R,S-sotalol in the plasma of patients with life-threatening cardiac arrhythmias. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10657059/),h,1.8,161469,DB00335,Atenolol
,10657059,AUC T,"Data obtained, expressed as mean, were: C MAX = 1230 ng/ml, T MAX = 1.8 h, AUC T = 10645 ng h-1 ml-1, Kab = 1.23 h-1, alpha = 0.95 h-1, ss = 0.09 h-1, t((1/2))ss = 7.8 h, ClT/F = 3.94 ml min-1 kg-1, and Vd/F = 2.53 l/kg.","A simple HPLC-fluorescence method for the measurement of R,S-sotalol in the plasma of patients with life-threatening cardiac arrhythmias. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10657059/),[ng] / [h·ml],10645,161470,DB00335,Atenolol
,10657059,Kab,"Data obtained, expressed as mean, were: C MAX = 1230 ng/ml, T MAX = 1.8 h, AUC T = 10645 ng h-1 ml-1, Kab = 1.23 h-1, alpha = 0.95 h-1, ss = 0.09 h-1, t((1/2))ss = 7.8 h, ClT/F = 3.94 ml min-1 kg-1, and Vd/F = 2.53 l/kg.","A simple HPLC-fluorescence method for the measurement of R,S-sotalol in the plasma of patients with life-threatening cardiac arrhythmias. ",Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10657059/),1/[h],1.23,161471,DB00335,Atenolol
,10657059,alpha,"Data obtained, expressed as mean, were: C MAX = 1230 ng/ml, T MAX = 1.8 h, AUC T = 10645 ng h-1 ml-1, Kab = 1.23 h-1, alpha = 0.95 h-1, ss = 0.09 h-1, t((1/2))ss = 7.8 h, ClT/F = 3.94 ml min-1 kg-1, and Vd/F = 2.53 l/kg.","A simple HPLC-fluorescence method for the measurement of R,S-sotalol in the plasma of patients with life-threatening cardiac arrhythmias. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10657059/),1/[h],0.95,161472,DB00335,Atenolol
,10657059,ss,"Data obtained, expressed as mean, were: C MAX = 1230 ng/ml, T MAX = 1.8 h, AUC T = 10645 ng h-1 ml-1, Kab = 1.23 h-1, alpha = 0.95 h-1, ss = 0.09 h-1, t((1/2))ss = 7.8 h, ClT/F = 3.94 ml min-1 kg-1, and Vd/F = 2.53 l/kg.","A simple HPLC-fluorescence method for the measurement of R,S-sotalol in the plasma of patients with life-threatening cardiac arrhythmias. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10657059/),1/[h],0.09,161473,DB00335,Atenolol
,10657059,t((1/2))ss,"Data obtained, expressed as mean, were: C MAX = 1230 ng/ml, T MAX = 1.8 h, AUC T = 10645 ng h-1 ml-1, Kab = 1.23 h-1, alpha = 0.95 h-1, ss = 0.09 h-1, t((1/2))ss = 7.8 h, ClT/F = 3.94 ml min-1 kg-1, and Vd/F = 2.53 l/kg.","A simple HPLC-fluorescence method for the measurement of R,S-sotalol in the plasma of patients with life-threatening cardiac arrhythmias. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10657059/),h,7.8,161474,DB00335,Atenolol
,10657059,ClT/F,"Data obtained, expressed as mean, were: C MAX = 1230 ng/ml, T MAX = 1.8 h, AUC T = 10645 ng h-1 ml-1, Kab = 1.23 h-1, alpha = 0.95 h-1, ss = 0.09 h-1, t((1/2))ss = 7.8 h, ClT/F = 3.94 ml min-1 kg-1, and Vd/F = 2.53 l/kg.","A simple HPLC-fluorescence method for the measurement of R,S-sotalol in the plasma of patients with life-threatening cardiac arrhythmias. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10657059/),[ml] / [kg·min],3.94,161475,DB00335,Atenolol
,10657059,Vd/F,"Data obtained, expressed as mean, were: C MAX = 1230 ng/ml, T MAX = 1.8 h, AUC T = 10645 ng h-1 ml-1, Kab = 1.23 h-1, alpha = 0.95 h-1, ss = 0.09 h-1, t((1/2))ss = 7.8 h, ClT/F = 3.94 ml min-1 kg-1, and Vd/F = 2.53 l/kg.","A simple HPLC-fluorescence method for the measurement of R,S-sotalol in the plasma of patients with life-threatening cardiac arrhythmias. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10657059/),[l] / [kg],2.53,161476,DB00335,Atenolol
better,22729617,absolute recovery,"The assay precision of the method was less than 6.4%, the assay accuracy ranged between 99.6% and 101.6%, and the absolute recovery of atenolol and internal standard was better than 66.1% and 76.2%, respectively.",Determination of atenolol in human plasma by HPLC with fluorescence detection: validation and application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22729617/),%,66.1,163782,DB00335,Atenolol
,22729617,absolute recovery,"The assay precision of the method was less than 6.4%, the assay accuracy ranged between 99.6% and 101.6%, and the absolute recovery of atenolol and internal standard was better than 66.1% and 76.2%, respectively.",Determination of atenolol in human plasma by HPLC with fluorescence detection: validation and application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22729617/),%,76.2,163783,DB00335,Atenolol
,7418712,elimination half-lives,"The atenolol elimination half-lives were 6.7 +/- 1.1 and 6.3 +/- 0.9 h, respectively, with and without chlorthalidone.",Pharmacokinetics of atenolol in hypertensive subjects with and without co-administration of chlorthalidone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7418712/),h,6.7,165878,DB00335,Atenolol
,7418712,elimination half-lives,"The atenolol elimination half-lives were 6.7 +/- 1.1 and 6.3 +/- 0.9 h, respectively, with and without chlorthalidone.",Pharmacokinetics of atenolol in hypertensive subjects with and without co-administration of chlorthalidone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7418712/),h,6.3,165879,DB00335,Atenolol
,8807020,apparent volume of distribution at steady state,"After i.v. administration, mean +/- SD apparent volume of distribution at steady state and systemic clearance values were 1,088 +/- 148 ml/kg and 259 +/- 72 ml/h/kg, respectively.",Pharmacokinetics of atenolol in clinically normal cats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8807020/),[ml] / [kg],"1,088",166372,DB00335,Atenolol
,8807020,systemic clearance,"After i.v. administration, mean +/- SD apparent volume of distribution at steady state and systemic clearance values were 1,088 +/- 148 ml/kg and 259 +/- 72 ml/h/kg, respectively.",Pharmacokinetics of atenolol in clinically normal cats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8807020/),[ml] / [h·kg],259,166373,DB00335,Atenolol
,8807020,Bioavailability,Bioavailability was 90 +/- 9% after oral administration.,Pharmacokinetics of atenolol in clinically normal cats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8807020/),%,90,166374,DB00335,Atenolol
,8807020,half-life,"The half-life values were 3.44 +/- 0.5 and 3.66 +/- 0.39 hours after i.v. and oral administrations, respectively.",Pharmacokinetics of atenolol in clinically normal cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8807020/),h,3.44,166375,DB00335,Atenolol
,8807020,half-life,"The half-life values were 3.44 +/- 0.5 and 3.66 +/- 0.39 hours after i.v. and oral administrations, respectively.",Pharmacokinetics of atenolol in clinically normal cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8807020/),h,3.66,166376,DB00335,Atenolol
,2951261,plasma half-life,Mean plasma concentrations of doxazosin were proportional to dose and the plasma half-life was 11.5 h and independent of dose.,The pharmacokinetics and pharmacodynamics of doxazosin compared with atenolol during long-term double-blind treatment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2951261/),h,11.5,166854,DB00335,Atenolol
,2280355,areas under the plasma concentration-time curves (AUCs,"After oral administration of 50 mg of racemic AT to humans, the areas under the plasma concentration-time curves (AUCs; mean +/- SD) were 1640 +/- 602 and 1860 +/- 652 (ng/mL)h for the S(-)- and R(+)-enantiomers, respectively (p less than 0.05).",Pharmacokinetics of atenolol enantiomers in humans and rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2280355/),h,1640,167090,DB00335,Atenolol
,2280355,areas under the plasma concentration-time curves (AUCs,"After oral administration of 50 mg of racemic AT to humans, the areas under the plasma concentration-time curves (AUCs; mean +/- SD) were 1640 +/- 602 and 1860 +/- 652 (ng/mL)h for the S(-)- and R(+)-enantiomers, respectively (p less than 0.05).",Pharmacokinetics of atenolol enantiomers in humans and rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2280355/),h,1860,167091,DB00335,Atenolol
,2280355,renal clearance (CLr,"The small difference in the AUC was a reflection of a slight, but statistically significant (p less than 0.05) difference in the renal clearance (CLr, mL/min) of the enantiomers [129 +/- 32, S(-)-AT; 120 +/- 29, R(+)-AT].",Pharmacokinetics of atenolol enantiomers in humans and rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2280355/),[ml] / [min],129,167092,DB00335,Atenolol
,2280355,renal clearance (CLr,"The small difference in the AUC was a reflection of a slight, but statistically significant (p less than 0.05) difference in the renal clearance (CLr, mL/min) of the enantiomers [129 +/- 32, S(-)-AT; 120 +/- 29, R(+)-AT].",Pharmacokinetics of atenolol enantiomers in humans and rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2280355/),[ml] / [min],120,167093,DB00335,Atenolol
,2280355,volume of distribution (V lambda,"However, the two enantiomers were not different from each other (p greater than 0.05) with respect to the volume of distribution (V lambda, L/kg) [0.879 +/- 0.342, S(-)-AT; 0.790 +/- 0.255, R(+)-AT] or the terminal elimination rate constant (lambda z, h-1) [0.113 +/- 0.038, S(-)-AT; 0.114 +/- 0.036, R(+)-AT].",Pharmacokinetics of atenolol enantiomers in humans and rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2280355/),[l] / [kg],0.879,167094,DB00335,Atenolol
,2280355,volume of distribution (V lambda,"However, the two enantiomers were not different from each other (p greater than 0.05) with respect to the volume of distribution (V lambda, L/kg) [0.879 +/- 0.342, S(-)-AT; 0.790 +/- 0.255, R(+)-AT] or the terminal elimination rate constant (lambda z, h-1) [0.113 +/- 0.038, S(-)-AT; 0.114 +/- 0.036, R(+)-AT].",Pharmacokinetics of atenolol enantiomers in humans and rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2280355/),[l] / [kg],0.790,167095,DB00335,Atenolol
,2280355,terminal elimination rate constant (lambda z,"However, the two enantiomers were not different from each other (p greater than 0.05) with respect to the volume of distribution (V lambda, L/kg) [0.879 +/- 0.342, S(-)-AT; 0.790 +/- 0.255, R(+)-AT] or the terminal elimination rate constant (lambda z, h-1) [0.113 +/- 0.038, S(-)-AT; 0.114 +/- 0.036, R(+)-AT].",Pharmacokinetics of atenolol enantiomers in humans and rats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2280355/),1/[h],0.113,167096,DB00335,Atenolol
,2280355,terminal elimination rate constant (lambda z,"However, the two enantiomers were not different from each other (p greater than 0.05) with respect to the volume of distribution (V lambda, L/kg) [0.879 +/- 0.342, S(-)-AT; 0.790 +/- 0.255, R(+)-AT] or the terminal elimination rate constant (lambda z, h-1) [0.113 +/- 0.038, S(-)-AT; 0.114 +/- 0.036, R(+)-AT].",Pharmacokinetics of atenolol enantiomers in humans and rats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2280355/),1/[h],0.114,167097,DB00335,Atenolol
,2280355,AUC,"After iv administration of 10 mg/kg of the racemic AT to rats, the R(+)-enantiomer achieved higher AUC values [(ng/mL)h] compared with its antipode (p less than 0.05) [3630 +/- 1040, S(-)-AT; 4020 +/- 1080, R(+)-AT].",Pharmacokinetics of atenolol enantiomers in humans and rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2280355/),[ng] / [ml)h],3630,167098,DB00335,Atenolol
,2280355,AUC,"After iv administration of 10 mg/kg of the racemic AT to rats, the R(+)-enantiomer achieved higher AUC values [(ng/mL)h] compared with its antipode (p less than 0.05) [3630 +/- 1040, S(-)-AT; 4020 +/- 1080, R(+)-AT].",Pharmacokinetics of atenolol enantiomers in humans and rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2280355/),[ng] / [ml)h],4020,167099,DB00335,Atenolol
,2280355,renal clearance,"Similar to the human results, this difference was due to a stereoselective renal clearance (mL/min/kg) in favor of S(-)-AT [14.9 +/- 5.78, S(-)-AT; 13.0 +/- 4.88, R(+)-AT; p less than 0.05].",Pharmacokinetics of atenolol enantiomers in humans and rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2280355/),[ml] / [kg·min],14.9,167100,DB00335,Atenolol
,2280355,renal clearance,"Similar to the human results, this difference was due to a stereoselective renal clearance (mL/min/kg) in favor of S(-)-AT [14.9 +/- 5.78, S(-)-AT; 13.0 +/- 4.88, R(+)-AT; p less than 0.05].",Pharmacokinetics of atenolol enantiomers in humans and rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2280355/),[ml] / [kg·min],13.0,167101,DB00335,Atenolol
,6125199,elimination half-life,A slight but significant increase in the elimination half-life from 6.5 +/- 0.6 to 7.9 +/- 0.6 (P less than 0.05) was noted for atenolol after pretreatment with cimetidine.,The effect of pretreatment with cimetidine on the bioavailability and disposition of atenolol and metoprolol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6125199/),,6.5,167150,DB00335,Atenolol
,6125199,elimination half-life,A slight but significant increase in the elimination half-life from 6.5 +/- 0.6 to 7.9 +/- 0.6 (P less than 0.05) was noted for atenolol after pretreatment with cimetidine.,The effect of pretreatment with cimetidine on the bioavailability and disposition of atenolol and metoprolol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6125199/),,7.9,167151,DB00335,Atenolol
,6749509,elimination half life,After oral administration elimination half life of atenolol is calculated from 6 to 9 h by different authors.,Clinical pharmacokinetics of atenolol--a review. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6749509/),h,6 to 9,169734,DB00335,Atenolol
,6749509,elimination half life,In patients with impaired renal function elimination half life of atenolol gradually increases to values of 36 h in uraemic patients (glomerular filtration rate (GFR) less than 10 ml/min).,Clinical pharmacokinetics of atenolol--a review. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6749509/),h,36,169735,DB00335,Atenolol
,21414851,detection limit (S/N=3),"The linear ranges of the standard solution for atenolol and esmolol were 2.5-125 μmol/L with a detection limit (S/N=3) of 0.5 μmol/L, and for metoprolol was 0.5-25 μmol/L with a detection limit of 0.1 μmol/L.",Determination of β-blockers in pharmaceutical and human urine by capillary electrophoresis with electrochemiluminescence detection and studies on the pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21414851/),[μM] / [l],0.5,177583,DB00335,Atenolol
,21414851,detection limit,"The linear ranges of the standard solution for atenolol and esmolol were 2.5-125 μmol/L with a detection limit (S/N=3) of 0.5 μmol/L, and for metoprolol was 0.5-25 μmol/L with a detection limit of 0.1 μmol/L.",Determination of β-blockers in pharmaceutical and human urine by capillary electrophoresis with electrochemiluminescence detection and studies on the pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21414851/),[μM] / [l],0.1,177584,DB00335,Atenolol
,21414851,recoveries,"The developed method was applied to the determination of metoprolol content in commercial pharmaceutical, and the analytical results are in good agreement with the nominal value with recoveries in the range of 98.7-105%.",Determination of β-blockers in pharmaceutical and human urine by capillary electrophoresis with electrochemiluminescence detection and studies on the pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21414851/),%,98.7-105,177585,DB00335,Atenolol
,31794668,clearance,"Pharmacokinetic parameters were obtained using a compartmental fitting approach, and the estimated clearance, volume of distribution, and half-life values were the following: atenolol (6.44 μL/min, 687 μL, and 73.87 min), timolol (19.30 μL/min, 937 μL, and 33.64 min), and betaxolol (32.20 μL/min, 1421 μL, and 30.58 min).","Ocular Intracameral Pharmacokinetics for a Cocktail of Timolol, Betaxolol, and Atenolol in Rabbits. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31794668/),[μl] / [min],6.44,180193,DB00335,Atenolol
,31794668,volume of distribution,"Pharmacokinetic parameters were obtained using a compartmental fitting approach, and the estimated clearance, volume of distribution, and half-life values were the following: atenolol (6.44 μL/min, 687 μL, and 73.87 min), timolol (19.30 μL/min, 937 μL, and 33.64 min), and betaxolol (32.20 μL/min, 1421 μL, and 30.58 min).","Ocular Intracameral Pharmacokinetics for a Cocktail of Timolol, Betaxolol, and Atenolol in Rabbits. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31794668/),μl,687,180194,DB00335,Atenolol
,31794668,volume of distribution,"Pharmacokinetic parameters were obtained using a compartmental fitting approach, and the estimated clearance, volume of distribution, and half-life values were the following: atenolol (6.44 μL/min, 687 μL, and 73.87 min), timolol (19.30 μL/min, 937 μL, and 33.64 min), and betaxolol (32.20 μL/min, 1421 μL, and 30.58 min).","Ocular Intracameral Pharmacokinetics for a Cocktail of Timolol, Betaxolol, and Atenolol in Rabbits. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31794668/),[μl] / [min],32.20,180195,DB00335,Atenolol
,31794668,half-life,"Pharmacokinetic parameters were obtained using a compartmental fitting approach, and the estimated clearance, volume of distribution, and half-life values were the following: atenolol (6.44 μL/min, 687 μL, and 73.87 min), timolol (19.30 μL/min, 937 μL, and 33.64 min), and betaxolol (32.20 μL/min, 1421 μL, and 30.58 min).","Ocular Intracameral Pharmacokinetics for a Cocktail of Timolol, Betaxolol, and Atenolol in Rabbits. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31794668/),min,73.87,180196,DB00335,Atenolol
,31794668,half-life,"Pharmacokinetic parameters were obtained using a compartmental fitting approach, and the estimated clearance, volume of distribution, and half-life values were the following: atenolol (6.44 μL/min, 687 μL, and 73.87 min), timolol (19.30 μL/min, 937 μL, and 33.64 min), and betaxolol (32.20 μL/min, 1421 μL, and 30.58 min).","Ocular Intracameral Pharmacokinetics for a Cocktail of Timolol, Betaxolol, and Atenolol in Rabbits. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31794668/),min,33.64,180197,DB00335,Atenolol
,31794668,half-life,"Pharmacokinetic parameters were obtained using a compartmental fitting approach, and the estimated clearance, volume of distribution, and half-life values were the following: atenolol (6.44 μL/min, 687 μL, and 73.87 min), timolol (19.30 μL/min, 937 μL, and 33.64 min), and betaxolol (32.20 μL/min, 1421 μL, and 30.58 min).","Ocular Intracameral Pharmacokinetics for a Cocktail of Timolol, Betaxolol, and Atenolol in Rabbits. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31794668/),[μl] / [min],32.20,180198,DB00335,Atenolol
,31794668,half-life,"Pharmacokinetic parameters were obtained using a compartmental fitting approach, and the estimated clearance, volume of distribution, and half-life values were the following: atenolol (6.44 μL/min, 687 μL, and 73.87 min), timolol (19.30 μL/min, 937 μL, and 33.64 min), and betaxolol (32.20 μL/min, 1421 μL, and 30.58 min).","Ocular Intracameral Pharmacokinetics for a Cocktail of Timolol, Betaxolol, and Atenolol in Rabbits. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31794668/),μl,1421,180199,DB00335,Atenolol
,31794668,half-life,"Pharmacokinetic parameters were obtained using a compartmental fitting approach, and the estimated clearance, volume of distribution, and half-life values were the following: atenolol (6.44 μL/min, 687 μL, and 73.87 min), timolol (19.30 μL/min, 937 μL, and 33.64 min), and betaxolol (32.20 μL/min, 1421 μL, and 30.58 min).","Ocular Intracameral Pharmacokinetics for a Cocktail of Timolol, Betaxolol, and Atenolol in Rabbits. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31794668/),min,30.58,180200,DB00335,Atenolol
,10379636,Cin,"Cin was significantly (P < 0.01) lower in the healthy elderly subjects [104 (12) vs 120 (14) ml x min(-2) x 1.73 m(-2) in the young], but remained within the normal range (> 90 ml x min(-2) x 1.73 m(-2)).",Renal handling of drugs in the healthy elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379636/),[1.73·ml] / [(m)^2·(min)^2],104,181416,DB00335,Atenolol
,10379636,Cin,"Cin was significantly (P < 0.01) lower in the healthy elderly subjects [104 (12) vs 120 (14) ml x min(-2) x 1.73 m(-2) in the young], but remained within the normal range (> 90 ml x min(-2) x 1.73 m(-2)).",Renal handling of drugs in the healthy elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379636/),[1.73·ml] / [(m)^2·(min)^2],120,181417,DB00335,Atenolol
>,10379636,Cin,"Cin was significantly (P < 0.01) lower in the healthy elderly subjects [104 (12) vs 120 (14) ml x min(-2) x 1.73 m(-2) in the young], but remained within the normal range (> 90 ml x min(-2) x 1.73 m(-2)).",Renal handling of drugs in the healthy elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379636/),[1.73·ml] / [(m)^2·(min)^2],90,181418,DB00335,Atenolol
,10379636,C(Cr),"In contrast, C(Cr) was even lower in healthy elderly subjects [95 (24) vs 121 (20) ml x min(-1) in the young], and the Cockroft-Gault clearance underestimated true glomerular filtration rate (GFR) even more seriously [74 (17) vs 122 (16) ml min(-1)].",Renal handling of drugs in the healthy elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379636/),[ml] / [min],95,181419,DB00335,Atenolol
,10379636,C(Cr),"In contrast, C(Cr) was even lower in healthy elderly subjects [95 (24) vs 121 (20) ml x min(-1) in the young], and the Cockroft-Gault clearance underestimated true glomerular filtration rate (GFR) even more seriously [74 (17) vs 122 (16) ml min(-1)].",Renal handling of drugs in the healthy elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379636/),[ml] / [min],121,181420,DB00335,Atenolol
,10379636,area under the curve (AUC),"For atenolol the mean area under the curve (AUC) was similar in both groups [3.16 (0.48) microg x h(-1) x ml(-1) in the elderly vs 3.01 (0.30) in the young], as was the mean maximal plasma concentration [0.42 (0.07) vs 0.44 (0.06) microg x ml(-1)], but the proportion of the drug excreted in urine was marginally (P < 0.025) lower in the elderly.",Renal handling of drugs in the healthy elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379636/),[μg] / [h·ml],3.16,181421,DB00335,Atenolol
,10379636,area under the curve (AUC),"For atenolol the mean area under the curve (AUC) was similar in both groups [3.16 (0.48) microg x h(-1) x ml(-1) in the elderly vs 3.01 (0.30) in the young], as was the mean maximal plasma concentration [0.42 (0.07) vs 0.44 (0.06) microg x ml(-1)], but the proportion of the drug excreted in urine was marginally (P < 0.025) lower in the elderly.",Renal handling of drugs in the healthy elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379636/),,3.01,181422,DB00335,Atenolol
,10379636,maximal plasma concentration,"For atenolol the mean area under the curve (AUC) was similar in both groups [3.16 (0.48) microg x h(-1) x ml(-1) in the elderly vs 3.01 (0.30) in the young], as was the mean maximal plasma concentration [0.42 (0.07) vs 0.44 (0.06) microg x ml(-1)], but the proportion of the drug excreted in urine was marginally (P < 0.025) lower in the elderly.",Renal handling of drugs in the healthy elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379636/),[μg] / [ml],0.42,181423,DB00335,Atenolol
,10379636,maximal plasma concentration,"For atenolol the mean area under the curve (AUC) was similar in both groups [3.16 (0.48) microg x h(-1) x ml(-1) in the elderly vs 3.01 (0.30) in the young], as was the mean maximal plasma concentration [0.42 (0.07) vs 0.44 (0.06) microg x ml(-1)], but the proportion of the drug excreted in urine was marginally (P < 0.025) lower in the elderly.",Renal handling of drugs in the healthy elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379636/),[μg] / [ml],0.44,181424,DB00335,Atenolol
,8331202,biologic half-life,"As the serum creatinine concentration returned slowly to baseline with good diuresis, the concentration of atenolol decreased (biologic half-life = 2.95 days) and the blood pressure gradually recovered.",Impaired elimination of atenolol in a nephropathic patient with self-medication overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8331202/),d,2.95,184252,DB00335,Atenolol
,19448909,biological half-life,A prolongation of propranolol biological half-life from 5.41 +/- 0.75 to 11.46 +/- 1.66 h (P = 0.0028) and an increase in propranolol volume of distribution from 8.70 +/- 2.83 to 19.33 +/- 6.52 L/kg (P = 0.0032) were observed after CABG with CPB.,Effect of cardiopulmonary bypass on the pharmacokinetics of propranolol and atenolol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19448909/),h,5.41,184673,DB00335,Atenolol
,19448909,biological half-life,A prolongation of propranolol biological half-life from 5.41 +/- 0.75 to 11.46 +/- 1.66 h (P = 0.0028) and an increase in propranolol volume of distribution from 8.70 +/- 2.83 to 19.33 +/- 6.52 L/kg (P = 0.0032) were observed after CABG with CPB.,Effect of cardiopulmonary bypass on the pharmacokinetics of propranolol and atenolol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19448909/),h,11.46,184674,DB00335,Atenolol
,19448909,volume of distribution,A prolongation of propranolol biological half-life from 5.41 +/- 0.75 to 11.46 +/- 1.66 h (P = 0.0028) and an increase in propranolol volume of distribution from 8.70 +/- 2.83 to 19.33 +/- 6.52 L/kg (P = 0.0032) were observed after CABG with CPB.,Effect of cardiopulmonary bypass on the pharmacokinetics of propranolol and atenolol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19448909/),[l] / [kg],8.70,184675,DB00335,Atenolol
,19448909,volume of distribution,A prolongation of propranolol biological half-life from 5.41 +/- 0.75 to 11.46 +/- 1.66 h (P = 0.0028) and an increase in propranolol volume of distribution from 8.70 +/- 2.83 to 19.33 +/- 6.52 L/kg (P = 0.0032) were observed after CABG with CPB.,Effect of cardiopulmonary bypass on the pharmacokinetics of propranolol and atenolol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19448909/),[l] / [kg],19.33,184676,DB00335,Atenolol
,19448909,biological half-life,No significant changes were observed in either atenolol biological half-life (from 11.20 +/- 1.60 to 11.44 +/- 2.89 h) or atenolol volume of distribution (from 2.90 +/- 0.36 to 3.83 +/- 0.72 L/kg).,Effect of cardiopulmonary bypass on the pharmacokinetics of propranolol and atenolol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19448909/),h,11.20,184677,DB00335,Atenolol
,19448909,biological half-life,No significant changes were observed in either atenolol biological half-life (from 11.20 +/- 1.60 to 11.44 +/- 2.89 h) or atenolol volume of distribution (from 2.90 +/- 0.36 to 3.83 +/- 0.72 L/kg).,Effect of cardiopulmonary bypass on the pharmacokinetics of propranolol and atenolol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19448909/),h,11.44,184678,DB00335,Atenolol
,19448909,volume of distribution,No significant changes were observed in either atenolol biological half-life (from 11.20 +/- 1.60 to 11.44 +/- 2.89 h) or atenolol volume of distribution (from 2.90 +/- 0.36 to 3.83 +/- 0.72 L/kg).,Effect of cardiopulmonary bypass on the pharmacokinetics of propranolol and atenolol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19448909/),[l] / [kg],2.90,184679,DB00335,Atenolol
,19448909,volume of distribution,No significant changes were observed in either atenolol biological half-life (from 11.20 +/- 1.60 to 11.44 +/- 2.89 h) or atenolol volume of distribution (from 2.90 +/- 0.36 to 3.83 +/- 0.72 L/kg).,Effect of cardiopulmonary bypass on the pharmacokinetics of propranolol and atenolol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19448909/),[l] / [kg],3.83,184680,DB00335,Atenolol
,3382466,Recovery,Recovery was between 82 and 98% from plasma and between 92 and 99% from urine.,Determination of sotalol in human body fluids for pharmacokinetic and toxicokinetic studies using high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3382466/),%,82 and 98,185902,DB00335,Atenolol
,3382466,Recovery,Recovery was between 82 and 98% from plasma and between 92 and 99% from urine.,Determination of sotalol in human body fluids for pharmacokinetic and toxicokinetic studies using high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3382466/),%,92 and 99,185903,DB00335,Atenolol
,3609072,terminal elimination half-life,"The average terminal elimination half-life for the drug was 2.5 h calculated from blood, dialysate or urinary data.",Pharmacokinetic and pharmacodynamic modelling of atenolol in rabbits maintained on continuous peritoneal dialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3609072/),h,2.5,186540,DB00335,Atenolol
,3609072,half-time,"The mean equilibration half-time of atenolol effect and blood concentrations was 0.7 and 1.5 h in normal and pathological states, respectively.",Pharmacokinetic and pharmacodynamic modelling of atenolol in rabbits maintained on continuous peritoneal dialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3609072/),h,0.7,186541,DB00335,Atenolol
,3609072,half-time,"The mean equilibration half-time of atenolol effect and blood concentrations was 0.7 and 1.5 h in normal and pathological states, respectively.",Pharmacokinetic and pharmacodynamic modelling of atenolol in rabbits maintained on continuous peritoneal dialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3609072/),h,1.5,186542,DB00335,Atenolol
,2051334,clearance (CLcr,Creatinine clearance (CLcr; mL/min/kg) in 9-day diabetic rats (8.98 +/- 3.02) was significantly higher than that in the controls (4.59 +/- 1.08).,Effect of experimental diabetes mellitus on the pharmacokinetics of atenolol enantiomers in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2051334/),[ml] / [kg·min],8.,188946,DB00335,Atenolol
,19659504,"AUC(ss,tau)","Mean olmesartan AUC(ss,tau) for olmesartan alone and with amlodipine were 2439 and 2388 ng h/mL and for olmesartan alone and with atenolol were 2340 and 2247 ng h/mL.",Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19659504/),[h·ng] / [ml],2439,189018,DB00335,Atenolol
,19659504,"AUC(ss,tau)","Mean olmesartan AUC(ss,tau) for olmesartan alone and with amlodipine were 2439 and 2388 ng h/mL and for olmesartan alone and with atenolol were 2340 and 2247 ng h/mL.",Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19659504/),[h·ng] / [ml],2388,189019,DB00335,Atenolol
,19659504,"AUC(ss,tau)","Mean olmesartan AUC(ss,tau) for olmesartan alone and with amlodipine were 2439 and 2388 ng h/mL and for olmesartan alone and with atenolol were 2340 and 2247 ng h/mL.",Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19659504/),[h·ng] / [ml],2340,189020,DB00335,Atenolol
,19659504,"AUC(ss,tau)","Mean olmesartan AUC(ss,tau) for olmesartan alone and with amlodipine were 2439 and 2388 ng h/mL and for olmesartan alone and with atenolol were 2340 and 2247 ng h/mL.",Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19659504/),[h·ng] / [ml],2247,189021,DB00335,Atenolol
,19659504,"C(ss,max)","Corresponding olmesartan C(ss,max) values were 465.7 and 439.5 ng/mL for amlodipine, and 447.4 and 423.8 ng/mL for atenolol.",Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19659504/),[ng] / [ml],465.7,189022,DB00335,Atenolol
,19659504,"C(ss,max)","Corresponding olmesartan C(ss,max) values were 465.7 and 439.5 ng/mL for amlodipine, and 447.4 and 423.8 ng/mL for atenolol.",Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19659504/),[ng] / [ml],439.5,189023,DB00335,Atenolol
,19659504,"C(ss,max)","Corresponding olmesartan C(ss,max) values were 465.7 and 439.5 ng/mL for amlodipine, and 447.4 and 423.8 ng/mL for atenolol.",Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19659504/),[ng] / [ml],447.4,189024,DB00335,Atenolol
,19659504,"C(ss,max)","Corresponding olmesartan C(ss,max) values were 465.7 and 439.5 ng/mL for amlodipine, and 447.4 and 423.8 ng/mL for atenolol.",Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19659504/),[ng] / [ml],423.8,189025,DB00335,Atenolol
,19659504,t(max),Median t(max) values for olmesartan were 1.5 h for each group in each study.,Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19659504/),h,1.5,189026,DB00335,Atenolol
,12350290,pA(2),"HCl 6 is a highly specific beta(1)-adrenoceptor antagonist (pA(2) = 8.15+/-0.22, beta(1)/beta(2) selectivity > 4400).","Synthesis, beta-adrenoceptor pharmacology and toxicology of S-(-)-1-(4-(2-ethoxyethoxy)phenoxy)-2-hydroxy-3-(2-(3,4-dimethoxyphenyl)ethylamino)propane hydrochloride, a short acting beta(1)-specific antagonist. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12350290/),,8.15,189193,DB00335,Atenolol
>,12350290,beta(1)/beta(2) selectivity,"HCl 6 is a highly specific beta(1)-adrenoceptor antagonist (pA(2) = 8.15+/-0.22, beta(1)/beta(2) selectivity > 4400).","Synthesis, beta-adrenoceptor pharmacology and toxicology of S-(-)-1-(4-(2-ethoxyethoxy)phenoxy)-2-hydroxy-3-(2-(3,4-dimethoxyphenyl)ethylamino)propane hydrochloride, a short acting beta(1)-specific antagonist. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12350290/),,4400,189194,DB00335,Atenolol
<,12350290,half-life,HCl 6 and esmolol have very short durations of action after intravenous infusion in the rat (pharmacodynamic half-life is < 15 min for D140S.HCl and 10 min for esmolol).,"Synthesis, beta-adrenoceptor pharmacology and toxicology of S-(-)-1-(4-(2-ethoxyethoxy)phenoxy)-2-hydroxy-3-(2-(3,4-dimethoxyphenyl)ethylamino)propane hydrochloride, a short acting beta(1)-specific antagonist. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12350290/),min,15,189195,DB00335,Atenolol
,12350290,half-life,HCl 6 and esmolol have very short durations of action after intravenous infusion in the rat (pharmacodynamic half-life is < 15 min for D140S.HCl and 10 min for esmolol).,"Synthesis, beta-adrenoceptor pharmacology and toxicology of S-(-)-1-(4-(2-ethoxyethoxy)phenoxy)-2-hydroxy-3-(2-(3,4-dimethoxyphenyl)ethylamino)propane hydrochloride, a short acting beta(1)-specific antagonist. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12350290/),min,10,189196,DB00335,Atenolol
,2338117,maximal plasma atenolol concentration,"There was no change in the elimination parameters of atenolol, but the maximal plasma atenolol concentration was increased (1.66 to 7.37 mg.l-1) as was the AUC (14.9 to 52.1 mg.l-1.h) when the hypothyroidism had been treated.",Evolution of atenolol kinetics when hypothyroidism is corrected. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2338117/),[mg] / [l],1.66 to 7.37,190033,DB00335,Atenolol
,2338117,AUC,"There was no change in the elimination parameters of atenolol, but the maximal plasma atenolol concentration was increased (1.66 to 7.37 mg.l-1) as was the AUC (14.9 to 52.1 mg.l-1.h) when the hypothyroidism had been treated.",Evolution of atenolol kinetics when hypothyroidism is corrected. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2338117/),[h·mg] / [l],14.9 to 52.1,190034,DB00335,Atenolol
,7002567,peak plasma concentration,"The peak plasma concentration of atenolol (about 600 ng/ml) was found 3 h after administration of the first dose, and measurable amounts (50-70 ng/ml) were found after 24 h.",Time-course of the anti-hypertensive action of atenolol: comparison of response to first dose and to maintained oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7002567/),[ng] / [ml],600,191675,DB00335,Atenolol
,7002567,peak plasma concentration,"The peak plasma concentration of atenolol (about 600 ng/ml) was found 3 h after administration of the first dose, and measurable amounts (50-70 ng/ml) were found after 24 h.",Time-course of the anti-hypertensive action of atenolol: comparison of response to first dose and to maintained oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7002567/),[ng] / [ml],50-70,191676,DB00335,Atenolol
,22791245,Cmax,"The mean ± standard deviation (SD) values of the Cmax, Tmax, AUC0-24 h, AUC0-∞, ke, and t1/2 of the test and reference formulations were 268.4 (78.96) and 256.9 (79.34), 2.750 (0.9555) and 3.104 (1.053), 1 981 (729.2) and 1 872 (604.8), 2228 (697.1) and 2 187 (628.5), 0.1332 (0.02748) and 0.1421 (0.04223), 5.419 (1.110) and 5.442 (2.357), respectively.",Comparative pharmacokinetics and bioequivalence of two 50 mg atenolol tablet formulations in healthy Korean male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22791245/),,268.4,195547,DB00335,Atenolol
,22791245,t1/2,"The mean ± standard deviation (SD) values of the Cmax, Tmax, AUC0-24 h, AUC0-∞, ke, and t1/2 of the test and reference formulations were 268.4 (78.96) and 256.9 (79.34), 2.750 (0.9555) and 3.104 (1.053), 1 981 (729.2) and 1 872 (604.8), 2228 (697.1) and 2 187 (628.5), 0.1332 (0.02748) and 0.1421 (0.04223), 5.419 (1.110) and 5.442 (2.357), respectively.",Comparative pharmacokinetics and bioequivalence of two 50 mg atenolol tablet formulations in healthy Korean male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22791245/),,2 187,195548,DB00335,Atenolol
,22791245,t1/2,"The mean ± standard deviation (SD) values of the Cmax, Tmax, AUC0-24 h, AUC0-∞, ke, and t1/2 of the test and reference formulations were 268.4 (78.96) and 256.9 (79.34), 2.750 (0.9555) and 3.104 (1.053), 1 981 (729.2) and 1 872 (604.8), 2228 (697.1) and 2 187 (628.5), 0.1332 (0.02748) and 0.1421 (0.04223), 5.419 (1.110) and 5.442 (2.357), respectively.",Comparative pharmacokinetics and bioequivalence of two 50 mg atenolol tablet formulations in healthy Korean male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22791245/),,0.1332,195549,DB00335,Atenolol
,22791245,t1/2,"The mean ± standard deviation (SD) values of the Cmax, Tmax, AUC0-24 h, AUC0-∞, ke, and t1/2 of the test and reference formulations were 268.4 (78.96) and 256.9 (79.34), 2.750 (0.9555) and 3.104 (1.053), 1 981 (729.2) and 1 872 (604.8), 2228 (697.1) and 2 187 (628.5), 0.1332 (0.02748) and 0.1421 (0.04223), 5.419 (1.110) and 5.442 (2.357), respectively.",Comparative pharmacokinetics and bioequivalence of two 50 mg atenolol tablet formulations in healthy Korean male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22791245/),,0.1421,195550,DB00335,Atenolol
,22791245,t1/2,"The mean ± standard deviation (SD) values of the Cmax, Tmax, AUC0-24 h, AUC0-∞, ke, and t1/2 of the test and reference formulations were 268.4 (78.96) and 256.9 (79.34), 2.750 (0.9555) and 3.104 (1.053), 1 981 (729.2) and 1 872 (604.8), 2228 (697.1) and 2 187 (628.5), 0.1332 (0.02748) and 0.1421 (0.04223), 5.419 (1.110) and 5.442 (2.357), respectively.",Comparative pharmacokinetics and bioequivalence of two 50 mg atenolol tablet formulations in healthy Korean male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22791245/),,5.419,195551,DB00335,Atenolol
,22791245,t1/2,"The mean ± standard deviation (SD) values of the Cmax, Tmax, AUC0-24 h, AUC0-∞, ke, and t1/2 of the test and reference formulations were 268.4 (78.96) and 256.9 (79.34), 2.750 (0.9555) and 3.104 (1.053), 1 981 (729.2) and 1 872 (604.8), 2228 (697.1) and 2 187 (628.5), 0.1332 (0.02748) and 0.1421 (0.04223), 5.419 (1.110) and 5.442 (2.357), respectively.",Comparative pharmacokinetics and bioequivalence of two 50 mg atenolol tablet formulations in healthy Korean male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22791245/),,5.442,195552,DB00335,Atenolol
,3304770,terminal half-life,"Compared with conventionally formulated propranolol, long acting propranolol has a prolonged terminal half-life (8 to 11 hours), due to slower absorption from the gut.",Pharmacokinetics of long acting propranolol. Implications for therapeutic use. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3304770/),h,8 to 11,195556,DB00335,Atenolol
less,3304770,Systemic bioavailability,Systemic bioavailability of long acting propranolol is 30 to 50% less than that of the conventional formulation.,Pharmacokinetics of long acting propranolol. Implications for therapeutic use. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3304770/),%,30 to 50,195557,DB00335,Atenolol
,18969756,detection limit,The detection limit (signal-to-noise ratio = 3) was 1ngml(-1) salbutamol.,A simple method for the study of salbutamol pharmacokinetics by ion chromatography with direct conductivity detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18969756/),1/[ngml],3,196354,DB00335,Atenolol
,18969756,detection limit,The detection limit (signal-to-noise ratio = 3) was 1ngml(-1) salbutamol.,A simple method for the study of salbutamol pharmacokinetics by ion chromatography with direct conductivity detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18969756/),1/[ngml],1,196355,DB00335,Atenolol
,18969756,signal-to-noise ratio,The detection limit (signal-to-noise ratio = 3) was 1ngml(-1) salbutamol.,A simple method for the study of salbutamol pharmacokinetics by ion chromatography with direct conductivity detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18969756/),1/[ngml],3,196356,DB00335,Atenolol
,18969756,signal-to-noise ratio,The detection limit (signal-to-noise ratio = 3) was 1ngml(-1) salbutamol.,A simple method for the study of salbutamol pharmacokinetics by ion chromatography with direct conductivity detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18969756/),1/[ngml],1,196357,DB00335,Atenolol
,1888640,elimination half-life,3. In the first NA experiment NA 7CH significantly shortened the elimination half-life of NA from 8.6 +/- 2.2 (placebo) to 6.4 +/- 1.6 h (NA 7CH).,The effect of infinitesimal drug dilutions on the pharmacokinetics of nalidixic acid and atenolol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1888640/),h,8.6,199346,DB00335,Atenolol
,1888640,elimination half-life,3. In the first NA experiment NA 7CH significantly shortened the elimination half-life of NA from 8.6 +/- 2.2 (placebo) to 6.4 +/- 1.6 h (NA 7CH).,The effect of infinitesimal drug dilutions on the pharmacokinetics of nalidixic acid and atenolol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1888640/),h,6.4,199347,DB00335,Atenolol
,25915108,apparent permeability,"3. In vitro permeability studies from apical-to-basal direction conducted in Caco-2 cells and MDCK-II cells showed that etamicastat apparent permeability was 1.2 × 10(-5) and 1.1 × 10(-6 )cm/s, respectively, 5- and 50-fold lower as compared to nepicastat.",Role of P-glycoprotein and permeability upon the brain distribution and pharmacodynamics of etamicastat: a comparison with nepicastat. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25915108/),[cm] / [s],1.2 × 10(-5),203539,DB00335,Atenolol
,25915108,apparent permeability,"3. In vitro permeability studies from apical-to-basal direction conducted in Caco-2 cells and MDCK-II cells showed that etamicastat apparent permeability was 1.2 × 10(-5) and 1.1 × 10(-6 )cm/s, respectively, 5- and 50-fold lower as compared to nepicastat.",Role of P-glycoprotein and permeability upon the brain distribution and pharmacodynamics of etamicastat: a comparison with nepicastat. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25915108/),[cm] / [s],1.1 × 10(-6 ),203540,DB00335,Atenolol
greater,25915108,efflux ratio,"The secretory efflux ratio in MDCK-II cells overexpressing human P-gp showed an efflux ratio greater than 2, for both compounds, which was significantly decreased by elacridar.",Role of P-glycoprotein and permeability upon the brain distribution and pharmacodynamics of etamicastat: a comparison with nepicastat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25915108/),,2,203541,DB00335,Atenolol
,25915108,plasma free fraction,"Despite its lower bioavailability and higher clearance, as compared to nepicastat, etamicastat showed preferential distribution to peripheral tissues and high plasma free fraction (15.5%), which may explain its effects upon peripheral DBH and catecholamine levels.",Role of P-glycoprotein and permeability upon the brain distribution and pharmacodynamics of etamicastat: a comparison with nepicastat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25915108/),%,15.5,203542,DB00335,Atenolol
,8818030,detection limit,The assay has a wide range (10-5000 ng ml-1) of linearity and a detection limit of 5 ng ml-1 (or 0.1 ng per injection) with acceptable intra- and inter-assay reproducibilities using small volumes of plasma (100 microliters).,A micro liquid chromatographic assay for the determination of plasma-unbound atenolol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8818030/),[ng] / [ml],5,205492,DB00335,Atenolol
,8818030,detection limit,The assay has a wide range (10-5000 ng ml-1) of linearity and a detection limit of 5 ng ml-1 (or 0.1 ng per injection) with acceptable intra- and inter-assay reproducibilities using small volumes of plasma (100 microliters).,A micro liquid chromatographic assay for the determination of plasma-unbound atenolol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8818030/),[ng] / [injection],0.1,205493,DB00335,Atenolol
,32946960,o,"The ocular bioavailability was covering broad range of values: atenolol (0.07 %), timolol (1.22%, 1.51%) and betaxolol (3.82%, 4.31%).","Topical ocular pharmacokinetics and bioavailability for a cocktail of atenolol, timolol and betaxolol in rabbits. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32946960/),%,0.07,207370,DB00335,Atenolol
,32946960,o,"The ocular bioavailability was covering broad range of values: atenolol (0.07 %), timolol (1.22%, 1.51%) and betaxolol (3.82%, 4.31%).","Topical ocular pharmacokinetics and bioavailability for a cocktail of atenolol, timolol and betaxolol in rabbits. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32946960/),%,1.22,207371,DB00335,Atenolol
,32946960,o,"The ocular bioavailability was covering broad range of values: atenolol (0.07 %), timolol (1.22%, 1.51%) and betaxolol (3.82%, 4.31%).","Topical ocular pharmacokinetics and bioavailability for a cocktail of atenolol, timolol and betaxolol in rabbits. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32946960/),%,1.51,207372,DB00335,Atenolol
,32946960,o,"The ocular bioavailability was covering broad range of values: atenolol (0.07 %), timolol (1.22%, 1.51%) and betaxolol (3.82%, 4.31%).","Topical ocular pharmacokinetics and bioavailability for a cocktail of atenolol, timolol and betaxolol in rabbits. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32946960/),%,3.82,207373,DB00335,Atenolol
,32946960,o,"The ocular bioavailability was covering broad range of values: atenolol (0.07 %), timolol (1.22%, 1.51%) and betaxolol (3.82%, 4.31%).","Topical ocular pharmacokinetics and bioavailability for a cocktail of atenolol, timolol and betaxolol in rabbits. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32946960/),%,4.31,207374,DB00335,Atenolol
,2726683,constant partition ratio,"The relationship of atenolol concentrations from plasma and CSF in these animals was linear, with a constant partition ratio of 0.02.",Nonlinear distribution of atenolol between plasma and cerebrospinal fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2726683/),,0.02,209185,DB00335,Atenolol
,22718748,recovery,The mean recovery of atenolol was 98.4% for plasma.,HPLC method for determination of atenolol in human plasma and application to a pharmacokinetic study in Turkey. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22718748/),%,98.4,210188,DB00335,Atenolol
,22718748,limits of detection,"The limits of detection and quantification of atenolol were 1.5 and 5 ng/mL, respectively.",HPLC method for determination of atenolol in human plasma and application to a pharmacokinetic study in Turkey. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22718748/),[ng] / [ml],1.5,210189,DB00335,Atenolol
,22718748,limits of detection,"The limits of detection and quantification of atenolol were 1.5 and 5 ng/mL, respectively.",HPLC method for determination of atenolol in human plasma and application to a pharmacokinetic study in Turkey. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22718748/),[ng] / [ml],5,210190,DB00335,Atenolol
,2439812,elimination half-life,"In pharmacokinetic terms, however, these drugs show no pronounced difference in their elimination half-life (ranging between 4 and 8 h).",Pharmacodynamic models of various beta blockers: an explanation for the long duration of action of bopindolol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439812/),h,4 and 8,210689,DB00335,Atenolol
,12856830,elimination rate constant,"As for the lipophilic drug propranolol, a significant decrease in elimination rate constant was found (from 0.24 +/- 0.08 h(-1) to 0.16 +/- 0.04 h(-1), p < 0.03) in comparison to normolipemic subjects.",Comparative pharmacokinetics of propranolol and atenolol in primary hyperlipidemia. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12856830/),1/[h],0.24,210857,DB00335,Atenolol
,12856830,elimination rate constant,"As for the lipophilic drug propranolol, a significant decrease in elimination rate constant was found (from 0.24 +/- 0.08 h(-1) to 0.16 +/- 0.04 h(-1), p < 0.03) in comparison to normolipemic subjects.",Comparative pharmacokinetics of propranolol and atenolol in primary hyperlipidemia. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12856830/),1/[h],0.16,210858,DB00335,Atenolol
,12856830,area under the concentration-time curve,"In the case of the hydrophilic atenolol, the most marked alterations were also seen in subjects with mixed form of hyperlipidemia, especially significantly lower values of area under the concentration-time curve (8950.8 +/- 2060.5 ng/ml x h and 6715.4 +/- 1813.8 ng/ml x h, p < 0.05) as well as higher elimination rate constant (0.08 +/- 0.03 h(-1) and 0.13 +/- 0.05 h(-1), p < 0.05) in comparison with the controls, respectively.",Comparative pharmacokinetics of propranolol and atenolol in primary hyperlipidemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12856830/),[ng] / [h·ml],8950.8,210859,DB00335,Atenolol
,12856830,area under the concentration-time curve,"In the case of the hydrophilic atenolol, the most marked alterations were also seen in subjects with mixed form of hyperlipidemia, especially significantly lower values of area under the concentration-time curve (8950.8 +/- 2060.5 ng/ml x h and 6715.4 +/- 1813.8 ng/ml x h, p < 0.05) as well as higher elimination rate constant (0.08 +/- 0.03 h(-1) and 0.13 +/- 0.05 h(-1), p < 0.05) in comparison with the controls, respectively.",Comparative pharmacokinetics of propranolol and atenolol in primary hyperlipidemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12856830/),[ng] / [h·ml],6715.4,210860,DB00335,Atenolol
,12856830,elimination rate constant,"In the case of the hydrophilic atenolol, the most marked alterations were also seen in subjects with mixed form of hyperlipidemia, especially significantly lower values of area under the concentration-time curve (8950.8 +/- 2060.5 ng/ml x h and 6715.4 +/- 1813.8 ng/ml x h, p < 0.05) as well as higher elimination rate constant (0.08 +/- 0.03 h(-1) and 0.13 +/- 0.05 h(-1), p < 0.05) in comparison with the controls, respectively.",Comparative pharmacokinetics of propranolol and atenolol in primary hyperlipidemia. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12856830/),1/[h],0.08,210861,DB00335,Atenolol
,12856830,elimination rate constant,"In the case of the hydrophilic atenolol, the most marked alterations were also seen in subjects with mixed form of hyperlipidemia, especially significantly lower values of area under the concentration-time curve (8950.8 +/- 2060.5 ng/ml x h and 6715.4 +/- 1813.8 ng/ml x h, p < 0.05) as well as higher elimination rate constant (0.08 +/- 0.03 h(-1) and 0.13 +/- 0.05 h(-1), p < 0.05) in comparison with the controls, respectively.",Comparative pharmacokinetics of propranolol and atenolol in primary hyperlipidemia. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12856830/),1/[h],0.13,210862,DB00335,Atenolol
,21595025,flow rate,"Separation of analytes was achieved on an ODS column (100 mm length × 2.1 mm id, 3 μm) by a gradient elution with 10 mM formic acid and methanol by varying their proportion at a flow rate of 0.2 mL/min.",A highly sensitive LC-MS/MS method capable of simultaneously quantitating celiprolol and atenolol in human plasma for a cassette cold-microdosing study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21595025/),[ml] / [min],0.2,211812,DB00335,Atenolol
,7459427,elimination of half-life,The average elimination of half-life of atenolol was between 6 and 7 h for all three formulations.,Bioavailability of atenolol formulations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7459427/),h,6 and 7,214356,DB00335,Atenolol
,10709151,area under the change in diastolic blood pressure curve,"For area under the change in diastolic blood pressure curve, the reduction was significantly greater after tasosartan + atenolol compared with that after atenolol alone (336 +/- 85 and 190 +/- 71 mmHg.24 h; p < 0.05 for combination and atenolol alone, respectively; mean +/- SEM).",A pharmacokinetic and pharmacodynamic study of the potential drug interaction between tasosartan and atenolol in patients with stage 1 and 2 essential hypertension. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10709151/),24·h·mmhg,336,218276,DB00335,Atenolol
,10709151,area under the change in diastolic blood pressure curve,"For area under the change in diastolic blood pressure curve, the reduction was significantly greater after tasosartan + atenolol compared with that after atenolol alone (336 +/- 85 and 190 +/- 71 mmHg.24 h; p < 0.05 for combination and atenolol alone, respectively; mean +/- SEM).",A pharmacokinetic and pharmacodynamic study of the potential drug interaction between tasosartan and atenolol in patients with stage 1 and 2 essential hypertension. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10709151/),24·h·mmhg,190,218277,DB00335,Atenolol
,9367207,flow-rate,"The drugs were separated on an ODS column at room temperature using a 0.05 M sodium dodecyl sulphate in phosphate buffer (pH 5.8)-n-propanol (95:5, v/v) solution, delivered at a flow-rate of 1.3 ml/min.",Simultaneous determination of atenolol and chlorthalidone in plasma by high-performance liquid chromatography. Application to pharmacokinetic studies in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9367207/),[ml] / [min],1.3,219175,DB00335,Atenolol
,29089037,"unbound volume of distribution in brain (Vu, brain)","The unbound volume of distribution in brain (Vu, brain) of S-atenolol was also calculated as 0.69 ± 0.10 mL/g brain, indicating that S-atenolol is evenly distributed within brain parenchyma.",Revisiting atenolol as a low passive permeability marker. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29089037/),[ml] / [brain·g],0.69,219527,DB00335,Atenolol
,29089037,"unbound fraction (fu,brain)","Lastly, equilibrium dialysis showed limited nonspecific binding of S-atenolol in brain homogenate with an unbound fraction (fu,brain) of 0.88 ± 0.07.",Revisiting atenolol as a low passive permeability marker. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29089037/),,0.88,219528,DB00335,Atenolol
,11050696,C.I.,C.I. of chlortalidone were fully comprised in the 0.80-1.25 range.,Comparative bioavailability of two formulations containing atenolol and chlortalidone associated in a 4:1 fixed combination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11050696/),,0.80-1.25,219699,DB00335,Atenolol
,27469324,Systemic plasma clearance,"Systemic plasma clearance for the seven drugs ranged from low (1.1 ml/min/kg, theophylline) to close to liver blood flow (37.4 ml/min/kg, cimetidine).",Characterization of Pharmacokinetics in the Göttingen Minipig with Reference Human Drugs: An In Vitro and In Vivo Approach. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27469324/),[ml] / [kg·min],1.1,220371,DB00335,Atenolol
,27469324,Systemic plasma clearance,"Systemic plasma clearance for the seven drugs ranged from low (1.1 ml/min/kg, theophylline) to close to liver blood flow (37.4 ml/min/kg, cimetidine).",Characterization of Pharmacokinetics in the Göttingen Minipig with Reference Human Drugs: An In Vitro and In Vivo Approach. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27469324/),[ml] / [kg·min],37.4,220372,DB00335,Atenolol
,27469324,Volume of distribution,Volume of distribution in minipigs ranged from 0.7 L/kg for antipyrine to 3.2 L/kg for hydrochlorothiazide.,Characterization of Pharmacokinetics in the Göttingen Minipig with Reference Human Drugs: An In Vitro and In Vivo Approach. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27469324/),[l] / [kg],0.7,220373,DB00335,Atenolol
,27469324,Volume of distribution,Volume of distribution in minipigs ranged from 0.7 L/kg for antipyrine to 3.2 L/kg for hydrochlorothiazide.,Characterization of Pharmacokinetics in the Göttingen Minipig with Reference Human Drugs: An In Vitro and In Vivo Approach. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27469324/),[l] / [kg],3.2,220374,DB00335,Atenolol
,27469324,hepatocellularity,"The hepatocellularity for minipig was determined as 124 Mcells/g liver, similar to the values reported for human.",Characterization of Pharmacokinetics in the Göttingen Minipig with Reference Human Drugs: An In Vitro and In Vivo Approach. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27469324/),[Mcells] / [g],124,220375,DB00335,Atenolol
,9692658,resting heart rates,"Average resting heart rates (TT 68+/-10, PP 62+/-9 beats/min) and maximum heart rate during exercise (TT 100+/-6, PP 87+/-7 beats/min) were significantly higher in the third trimester than postpartum (p<0.05).",Pharmacokinetic and pharmacodynamic evaluation of atenolol during and after pregnancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9692658/),[beats] / [min],68,220438,DB00335,Atenolol
,9692658,resting heart rates,"Average resting heart rates (TT 68+/-10, PP 62+/-9 beats/min) and maximum heart rate during exercise (TT 100+/-6, PP 87+/-7 beats/min) were significantly higher in the third trimester than postpartum (p<0.05).",Pharmacokinetic and pharmacodynamic evaluation of atenolol during and after pregnancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9692658/),[beats] / [min],62,220439,DB00335,Atenolol
,9692658,maximum heart rate during exercise,"Average resting heart rates (TT 68+/-10, PP 62+/-9 beats/min) and maximum heart rate during exercise (TT 100+/-6, PP 87+/-7 beats/min) were significantly higher in the third trimester than postpartum (p<0.05).",Pharmacokinetic and pharmacodynamic evaluation of atenolol during and after pregnancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9692658/),[beats] / [min],100,220440,DB00335,Atenolol
,9692658,maximum heart rate during exercise,"Average resting heart rates (TT 68+/-10, PP 62+/-9 beats/min) and maximum heart rate during exercise (TT 100+/-6, PP 87+/-7 beats/min) were significantly higher in the third trimester than postpartum (p<0.05).",Pharmacokinetic and pharmacodynamic evaluation of atenolol during and after pregnancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9692658/),[beats] / [min],87,220441,DB00335,Atenolol
,9692658,area under the curve,"The 12-hour atenolol area under the curve (TT 0.208+/-0.061, PP 0.215+/-0.089 ng/ml/day) and maximum plasma concentrations during the time of exercise tests (TT 1.07+/-0.39, PP 1.14+/-0.53 mmol/L) were not significantly different.",Pharmacokinetic and pharmacodynamic evaluation of atenolol during and after pregnancy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9692658/),[ng] / [d·ml],0.208,220442,DB00335,Atenolol
,9692658,area under the curve,"The 12-hour atenolol area under the curve (TT 0.208+/-0.061, PP 0.215+/-0.089 ng/ml/day) and maximum plasma concentrations during the time of exercise tests (TT 1.07+/-0.39, PP 1.14+/-0.53 mmol/L) were not significantly different.",Pharmacokinetic and pharmacodynamic evaluation of atenolol during and after pregnancy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9692658/),[ng] / [d·ml],0.215,220443,DB00335,Atenolol
,9692658,maximum plasma concentrations,"The 12-hour atenolol area under the curve (TT 0.208+/-0.061, PP 0.215+/-0.089 ng/ml/day) and maximum plasma concentrations during the time of exercise tests (TT 1.07+/-0.39, PP 1.14+/-0.53 mmol/L) were not significantly different.",Pharmacokinetic and pharmacodynamic evaluation of atenolol during and after pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9692658/),[mM] / [l],1.07,220444,DB00335,Atenolol
,9692658,maximum plasma concentrations,"The 12-hour atenolol area under the curve (TT 0.208+/-0.061, PP 0.215+/-0.089 ng/ml/day) and maximum plasma concentrations during the time of exercise tests (TT 1.07+/-0.39, PP 1.14+/-0.53 mmol/L) were not significantly different.",Pharmacokinetic and pharmacodynamic evaluation of atenolol during and after pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9692658/),[mM] / [l],1.14,220445,DB00335,Atenolol
,15135092,recovery,The average recovery for terbutaline was 87.4% from plasma.,Simple determination of terbutaline in dog plasma by column-switching liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15135092/),%,87.4,220839,DB00335,Atenolol
,2434747,terminal elimination half life (t1/2),"After intravenous (i.v.) administration of 50 mg of the drug, there was a biexponential decline in plasma levels with a terminal elimination half life (t1/2) of 1.9 h (range 1.4-2.3 h) and a total apparent volume of distribution at equilibrium of 62 L.",Pharmacokinetics and concentration--effect relationships of bevantolol (CI-775) in normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2434747/),h,1.9,223465,DB00335,Atenolol
,2434747,total apparent volume of distribution at equilibrium,"After intravenous (i.v.) administration of 50 mg of the drug, there was a biexponential decline in plasma levels with a terminal elimination half life (t1/2) of 1.9 h (range 1.4-2.3 h) and a total apparent volume of distribution at equilibrium of 62 L.",Pharmacokinetics and concentration--effect relationships of bevantolol (CI-775) in normal volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2434747/),l,62,223466,DB00335,Atenolol
,2434747,bioavailability,"After oral administration of the same dose, the bioavailability averaged 57% (range 26-98%) and peak plasma levels varied over a threefold range.",Pharmacokinetics and concentration--effect relationships of bevantolol (CI-775) in normal volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2434747/),%,57,223467,DB00335,Atenolol
,1777376,apparent liver blood flow,3. The addition of nisoldipine was also associated with significant changes in apparent liver blood flow (measured by indocyanine green clearance) from 1.4 to 2.4 l min-1 in the atenolol group and from 1.3 to 2.3 l min-1 in the propranolol group.,The interactions between nisoldipine and two beta-adrenoceptor antagonists--atenolol and propranolol. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1777376/),[l] / [min],1.4 to 2.4,227822,DB00335,Atenolol
,1777376,apparent liver blood flow,3. The addition of nisoldipine was also associated with significant changes in apparent liver blood flow (measured by indocyanine green clearance) from 1.4 to 2.4 l min-1 in the atenolol group and from 1.3 to 2.3 l min-1 in the propranolol group.,The interactions between nisoldipine and two beta-adrenoceptor antagonists--atenolol and propranolol. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1777376/),[l] / [min],1.3 to 2.3,227823,DB00335,Atenolol
,29519953,dialytic clearance,"Using the recovery clearance method, the dialytic clearance values for atenolol, metoprolol, bisoprolol, and carvedilol were 72, 87, 44, and 0.2 ml/min, respectively (P<0.001).",β-Blocker Dialyzability in Maintenance Hemodialysis Patients: A Randomized Clinical Trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29519953/),[ml] / [min],72,234919,DB00335,Atenolol
,29519953,dialytic clearance,"Using the recovery clearance method, the dialytic clearance values for atenolol, metoprolol, bisoprolol, and carvedilol were 72, 87, 44, and 0.2 ml/min, respectively (P<0.001).",β-Blocker Dialyzability in Maintenance Hemodialysis Patients: A Randomized Clinical Trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29519953/),[ml] / [min],87,234920,DB00335,Atenolol
,29519953,dialytic clearance,"Using the recovery clearance method, the dialytic clearance values for atenolol, metoprolol, bisoprolol, and carvedilol were 72, 87, 44, and 0.2 ml/min, respectively (P<0.001).",β-Blocker Dialyzability in Maintenance Hemodialysis Patients: A Randomized Clinical Trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29519953/),[ml] / [min],44,234921,DB00335,Atenolol
,29519953,dialytic clearance,"Using the recovery clearance method, the dialytic clearance values for atenolol, metoprolol, bisoprolol, and carvedilol were 72, 87, 44, and 0.2 ml/min, respectively (P<0.001).",β-Blocker Dialyzability in Maintenance Hemodialysis Patients: A Randomized Clinical Trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29519953/),[ml] / [min],0.2,234922,DB00335,Atenolol
,29519953,dialytic clearance,"Applying the arterial venous difference method, the dialytic clearance values of atenolol, metoprolol, bisoprolol, and carvedilol were 167, 114, 96, and 24 ml/min, respectively (P<0.001).",β-Blocker Dialyzability in Maintenance Hemodialysis Patients: A Randomized Clinical Trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29519953/),[ml] / [min],167,234923,DB00335,Atenolol
,29519953,dialytic clearance,"Applying the arterial venous difference method, the dialytic clearance values of atenolol, metoprolol, bisoprolol, and carvedilol were 167, 114, 96, and 24 ml/min, respectively (P<0.001).",β-Blocker Dialyzability in Maintenance Hemodialysis Patients: A Randomized Clinical Trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29519953/),[ml] / [min],114,234924,DB00335,Atenolol
,29519953,dialytic clearance,"Applying the arterial venous difference method, the dialytic clearance values of atenolol, metoprolol, bisoprolol, and carvedilol were 167, 114, 96, and 24 ml/min, respectively (P<0.001).",β-Blocker Dialyzability in Maintenance Hemodialysis Patients: A Randomized Clinical Trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29519953/),[ml] / [min],96,234925,DB00335,Atenolol
,29519953,dialytic clearance,"Applying the arterial venous difference method, the dialytic clearance values of atenolol, metoprolol, bisoprolol, and carvedilol were 167, 114, 96, and 24 ml/min, respectively (P<0.001).",β-Blocker Dialyzability in Maintenance Hemodialysis Patients: A Randomized Clinical Trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29519953/),[ml] / [min],24,234926,DB00335,Atenolol
,1978546,plasma half-life,"Nadolol, with a plasma half-life of 15.5 hours, had the most pronounced heart rate-lowering effect 24 hours after the daily dose compared to pindolol, which had a half-life of 5.5 hours.",Beta-blocker duration of action and implications for therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1978546/),h,15.5,236741,DB00335,Atenolol
,1978546,half-life,"Nadolol, with a plasma half-life of 15.5 hours, had the most pronounced heart rate-lowering effect 24 hours after the daily dose compared to pindolol, which had a half-life of 5.5 hours.",Beta-blocker duration of action and implications for therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1978546/),h,5.5,236742,DB00335,Atenolol
,3730522,half-lives,"The mean half-lives were between 5 and 7 h, in agreement with other published data.",Bioavailability in man of atenolol and chlorthalidone from a combination formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3730522/),h,5 and 7,236876,DB00335,Atenolol
,3730522,peak blood concentrations,"The mean peak blood concentrations of chlorthalidone were 0.94, 1.00, and 0.99 micrograms ml-1 for the fixed and free combinations and the chlorthalidone tablet, respectively.",Bioavailability in man of atenolol and chlorthalidone from a combination formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3730522/),[μg] / [ml],0.94,236877,DB00335,Atenolol
,3730522,peak blood concentrations,"The mean peak blood concentrations of chlorthalidone were 0.94, 1.00, and 0.99 micrograms ml-1 for the fixed and free combinations and the chlorthalidone tablet, respectively.",Bioavailability in man of atenolol and chlorthalidone from a combination formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3730522/),[μg] / [ml],1.00,236878,DB00335,Atenolol
,3730522,peak blood concentrations,"The mean peak blood concentrations of chlorthalidone were 0.94, 1.00, and 0.99 micrograms ml-1 for the fixed and free combinations and the chlorthalidone tablet, respectively.",Bioavailability in man of atenolol and chlorthalidone from a combination formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3730522/),[μg] / [ml],0.99,236879,DB00335,Atenolol
,18803179,limit of detection,"The limit of detection was 0.1 ng/mL (S/N=3, sampling 90 s at 7 kV).",Sensitive analysis of donepezil in plasma by capillary electrophoresis combining on-column field-amplified sample stacking and its application in Alzheimer's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18803179/),[ng] / [ml],0.1,242001,DB00335,Atenolol
,18803179,S/N,"The limit of detection was 0.1 ng/mL (S/N=3, sampling 90 s at 7 kV).",Sensitive analysis of donepezil in plasma by capillary electrophoresis combining on-column field-amplified sample stacking and its application in Alzheimer's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18803179/),,3,242002,DB00335,Atenolol
,19716867,perfusion pressures,"Similar perfusion pressures (17.6+/-6.71 vs 17.7+/-8.87 cm H(2)O), lung wet/dry ratio (6.14+/-1.16 vs 5.16+/-0.87), physiological spaces, and permeability-surface area products were found for the two perfusates.",Influence of perfusate composition on drug disposition in the in-situ perfused rat lung. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19716867/),cm·h(2,17.6,242633,DB00335,Atenolol
,19716867,perfusion pressures,"Similar perfusion pressures (17.6+/-6.71 vs 17.7+/-8.87 cm H(2)O), lung wet/dry ratio (6.14+/-1.16 vs 5.16+/-0.87), physiological spaces, and permeability-surface area products were found for the two perfusates.",Influence of perfusate composition on drug disposition in the in-situ perfused rat lung. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19716867/),cm·h(2,17.7,242634,DB00335,Atenolol
,19716867,wet/dry ratio,"Similar perfusion pressures (17.6+/-6.71 vs 17.7+/-8.87 cm H(2)O), lung wet/dry ratio (6.14+/-1.16 vs 5.16+/-0.87), physiological spaces, and permeability-surface area products were found for the two perfusates.",Influence of perfusate composition on drug disposition in the in-situ perfused rat lung. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19716867/),,6.14,242635,DB00335,Atenolol
,19716867,wet/dry ratio,"Similar perfusion pressures (17.6+/-6.71 vs 17.7+/-8.87 cm H(2)O), lung wet/dry ratio (6.14+/-1.16 vs 5.16+/-0.87), physiological spaces, and permeability-surface area products were found for the two perfusates.",Influence of perfusate composition on drug disposition in the in-situ perfused rat lung. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19716867/),,5.16,242636,DB00335,Atenolol
,19716867,recovery,"However, the recovery of propranolol using perfusate A (49.3+/-10.1%) was significantly higher than that using perfusate B (38.9+/-9.91%).",Influence of perfusate composition on drug disposition in the in-situ perfused rat lung. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19716867/),%,49.3,242637,DB00335,Atenolol
,19716867,recovery,"However, the recovery of propranolol using perfusate A (49.3+/-10.1%) was significantly higher than that using perfusate B (38.9+/-9.91%).",Influence of perfusate composition on drug disposition in the in-situ perfused rat lung. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19716867/),%,38.9,242638,DB00335,Atenolol
,1970298,plasma elimination half-life (t1/2),The mean plasma elimination half-life (t1/2) increased from 12.9 to 13.2 h during steady state on bisoprolol and from 7.2 to 11.5 h on atenolol.,A randomized double-blind study of bisoprolol versus atenolol in mild to moderate essential hypertension. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1970298/),h,12.9 to 13.2,247472,DB00335,Atenolol
,1970298,plasma elimination half-life (t1/2),The mean plasma elimination half-life (t1/2) increased from 12.9 to 13.2 h during steady state on bisoprolol and from 7.2 to 11.5 h on atenolol.,A randomized double-blind study of bisoprolol versus atenolol in mild to moderate essential hypertension. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1970298/),h,7.2 to 11.5,247473,DB00335,Atenolol
,1970298,apparent volume of distribution (Vz),"The apparent volume of distribution (Vz) was greater for bisoprolol than for atenolol after single dosing (235 1 vs 146 1) and at steady state (216 1 vs 137 1), but clearances were similar for both drugs.",A randomized double-blind study of bisoprolol versus atenolol in mild to moderate essential hypertension. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1970298/),1,235,247474,DB00335,Atenolol
,1970298,apparent volume of distribution (Vz),"The apparent volume of distribution (Vz) was greater for bisoprolol than for atenolol after single dosing (235 1 vs 146 1) and at steady state (216 1 vs 137 1), but clearances were similar for both drugs.",A randomized double-blind study of bisoprolol versus atenolol in mild to moderate essential hypertension. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1970298/),1,146,247475,DB00335,Atenolol
,1970298,apparent volume of distribution (Vz),"The apparent volume of distribution (Vz) was greater for bisoprolol than for atenolol after single dosing (235 1 vs 146 1) and at steady state (216 1 vs 137 1), but clearances were similar for both drugs.",A randomized double-blind study of bisoprolol versus atenolol in mild to moderate essential hypertension. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1970298/),1,216,247476,DB00335,Atenolol
,1970298,apparent volume of distribution (Vz),"The apparent volume of distribution (Vz) was greater for bisoprolol than for atenolol after single dosing (235 1 vs 146 1) and at steady state (216 1 vs 137 1), but clearances were similar for both drugs.",A randomized double-blind study of bisoprolol versus atenolol in mild to moderate essential hypertension. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1970298/),1,137,247477,DB00335,Atenolol
> or =,11486824,absolute recoveries,The absolute recoveries for each analyte was > or = 95%.,Enantiomeric separation of metoprolol and alpha-hydroxymetoprolol by liquid chromatography and fluorescence detection using a chiral stationary phase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11486824/),%,95,250112,DB00335,Atenolol
,10125,elimination half-life,The peak plasma atenolol concentration occurred at 3 hr and thereafter declined exponentially with time with an elimination half-life of 6.36 +/- 0.55 hr: 43 +/- 3.9% of the dose was excreted in the urine within 72 hr.,"Clinical pharmacologic observations on atenolol, a beta-adrenoceptor blocker. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10125/),h,6.36,252301,DB00335,Atenolol
,10125,clearance,"After 50 mg intravenously, 100% of the dose was recovered from the urine, and the clearance was 97.3 ml/min.","Clinical pharmacologic observations on atenolol, a beta-adrenoceptor blocker. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10125/),[ml] / [min],97.3,252302,DB00335,Atenolol
,10125,bioavailability,Comparison of AUC O leads to chi after oral and intravenous administration of 50 mg showed the bioavailability to be 63% after oral drug.,"Clinical pharmacologic observations on atenolol, a beta-adrenoceptor blocker. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10125/),%,63,252303,DB00335,Atenolol
,10452127,Maximal plasma concentration (Cmax),Maximal plasma concentration (Cmax): l-Ate (331 +/- 79) micrograms.,Pharmacokinetics of atenolol enantiomers in 12 Chinese healthy men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10452127/),μg,331,255557,DB00335,Atenolol
,10452127,Area under blood concentration-time curve (AUC),Area under blood concentration-time curve (AUC): d-Ate (2635 +/- 610) micrograms.,Pharmacokinetics of atenolol enantiomers in 12 Chinese healthy men. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10452127/),μg,2635,255558,DB00335,Atenolol
,10452127,Renal clearance (Clr),"Renal clearance (Clr): l-Ate (6.9 +/- 1.2) L.h-1, d-Ate (6.5 +/- 1.3) L.h-1.",Pharmacokinetics of atenolol enantiomers in 12 Chinese healthy men. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10452127/),[l] / [h],6.9,255559,DB00335,Atenolol
,10452127,Renal clearance (Clr),"Renal clearance (Clr): l-Ate (6.9 +/- 1.2) L.h-1, d-Ate (6.5 +/- 1.3) L.h-1.",Pharmacokinetics of atenolol enantiomers in 12 Chinese healthy men. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10452127/),[l] / [h],6.5,255560,DB00335,Atenolol
,1490794,half time of elimination,The half time of elimination was calculated for A at 6.5 h and for S at 5.9 h.,Bioequivalence of a new atenolol formulation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1490794/),h,6.5,255903,DB00335,Atenolol
,1490794,half time of elimination,The half time of elimination was calculated for A at 6.5 h and for S at 5.9 h.,Bioequivalence of a new atenolol formulation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1490794/),h,5.9,255904,DB00335,Atenolol
,18162599,affinity (K(A)),The pharmacokinetic-pharmacodynamic relationship of isoprenaline was first characterized with the operational model of agonism using the literature value for the affinity (K(A)) of isoprenaline (3.2 x 10(-8) M; left atria WKY rats).,Mechanism-based pharmacodynamic modeling of S(-)-atenolol: estimation of in vivo affinity for the beta1-adrenoceptor with an agonist-antagonist interaction model. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18162599/),M,3.2 x 10(-8),257983,DB00335,Atenolol
,18162599,baseline (E(0)),"Resulting estimates for baseline (E(0)), maximal effect (E(max)), and efficacy (tau) were 374 (1.9%), 130 (5.9%), and 247 (33%) beats per minute, respectively.",Mechanism-based pharmacodynamic modeling of S(-)-atenolol: estimation of in vivo affinity for the beta1-adrenoceptor with an agonist-antagonist interaction model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18162599/),,374,257984,DB00335,Atenolol
,18162599,maximal effect (E(max)),"Resulting estimates for baseline (E(0)), maximal effect (E(max)), and efficacy (tau) were 374 (1.9%), 130 (5.9%), and 247 (33%) beats per minute, respectively.",Mechanism-based pharmacodynamic modeling of S(-)-atenolol: estimation of in vivo affinity for the beta1-adrenoceptor with an agonist-antagonist interaction model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18162599/),[beats] / [min],130,257985,DB00335,Atenolol
,18162599,efficacy (tau),"Resulting estimates for baseline (E(0)), maximal effect (E(max)), and efficacy (tau) were 374 (1.9%), 130 (5.9%), and 247 (33%) beats per minute, respectively.",Mechanism-based pharmacodynamic modeling of S(-)-atenolol: estimation of in vivo affinity for the beta1-adrenoceptor with an agonist-antagonist interaction model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18162599/),[beats] / [min],247,257986,DB00335,Atenolol
,18162599,affinity (K(B)),The estimated in vivo affinity (K(B)) of S(-)-atenolol for the beta(1) -receptor was 4.6 x 10(-8) M.,Mechanism-based pharmacodynamic modeling of S(-)-atenolol: estimation of in vivo affinity for the beta1-adrenoceptor with an agonist-antagonist interaction model. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18162599/),M,4.6 x 10(-8),257987,DB00335,Atenolol
,18162599,affinity,The obtained estimate for in vivo affinity of S(-)-atenolol (4.6 x 10(-8) M) is comparable to literature values for the in vitro affinity in functional assays.,Mechanism-based pharmacodynamic modeling of S(-)-atenolol: estimation of in vivo affinity for the beta1-adrenoceptor with an agonist-antagonist interaction model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18162599/),M,4.6 x 10(-8),257988,DB00335,Atenolol
,7461026,half life of elimination,The mean half life of elimination increased from 5.9 h in patients with normal renal function to 42.1 h in preuraemic patients (GFR less than 10 ml/min) following a single i.v. dose.,Pharmacokinetics of atenolol in relation to renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7461026/),h,5.9,259104,DB00335,Atenolol
,7461026,half life of elimination,The mean half life of elimination increased from 5.9 h in patients with normal renal function to 42.1 h in preuraemic patients (GFR less than 10 ml/min) following a single i.v. dose.,Pharmacokinetics of atenolol in relation to renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7461026/),h,42.1,259105,DB00335,Atenolol
,7461026,peak plasma concentrations,Mean peak plasma concentrations increased from 540 ng/ml in patients with normal renal function to 1493 ng/ml in preuraemic patients following chronic oral treatment with 100 mg/day.,Pharmacokinetics of atenolol in relation to renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7461026/),[ng] / [ml],540,259106,DB00335,Atenolol
,7461026,peak plasma concentrations,Mean peak plasma concentrations increased from 540 ng/ml in patients with normal renal function to 1493 ng/ml in preuraemic patients following chronic oral treatment with 100 mg/day.,Pharmacokinetics of atenolol in relation to renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7461026/),[ng] / [ml],1493,259107,DB00335,Atenolol
,7461026,half life of elimination,The mean half life of elimination during a single haemodialysis treatment was 4.3 h.,Pharmacokinetics of atenolol in relation to renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7461026/),h,4.3,259108,DB00335,Atenolol
,16431379,Peak plasma concentration (Cmax),"Peak plasma concentration (Cmax): 1.33 +/- 0.31 microg/ml, time to peak plasma concentration (Tmax): 2.2 +/- 0.27 hours, AUC (area under the plasma concentration-time curve) 6.34 +/- 2.1 microg-hr/ml for 100 mg tab and Cmax: 1.07 +/- 0.23 microg/ml, Tmax: 2.5 +/- 0.35 hours, AUC 4.97 +/- 1.09 microg-hr/ml for 50 mg (two pills) tab were observed.",Biopharmaceutical evaluation of oral tablet Atenolol (100 and 50 mg) on local population. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16431379/),[μg] / [ml],1.33,260791,DB00335,Atenolol
,16431379,time to peak plasma concentration (Tmax),"Peak plasma concentration (Cmax): 1.33 +/- 0.31 microg/ml, time to peak plasma concentration (Tmax): 2.2 +/- 0.27 hours, AUC (area under the plasma concentration-time curve) 6.34 +/- 2.1 microg-hr/ml for 100 mg tab and Cmax: 1.07 +/- 0.23 microg/ml, Tmax: 2.5 +/- 0.35 hours, AUC 4.97 +/- 1.09 microg-hr/ml for 50 mg (two pills) tab were observed.",Biopharmaceutical evaluation of oral tablet Atenolol (100 and 50 mg) on local population. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16431379/),h,2.2,260792,DB00335,Atenolol
,16431379,AUC (area under the plasma concentration-time curve),"Peak plasma concentration (Cmax): 1.33 +/- 0.31 microg/ml, time to peak plasma concentration (Tmax): 2.2 +/- 0.27 hours, AUC (area under the plasma concentration-time curve) 6.34 +/- 2.1 microg-hr/ml for 100 mg tab and Cmax: 1.07 +/- 0.23 microg/ml, Tmax: 2.5 +/- 0.35 hours, AUC 4.97 +/- 1.09 microg-hr/ml for 50 mg (two pills) tab were observed.",Biopharmaceutical evaluation of oral tablet Atenolol (100 and 50 mg) on local population. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16431379/),[μg-hr] / [ml],6.34,260793,DB00335,Atenolol
,16431379,Cmax,"Peak plasma concentration (Cmax): 1.33 +/- 0.31 microg/ml, time to peak plasma concentration (Tmax): 2.2 +/- 0.27 hours, AUC (area under the plasma concentration-time curve) 6.34 +/- 2.1 microg-hr/ml for 100 mg tab and Cmax: 1.07 +/- 0.23 microg/ml, Tmax: 2.5 +/- 0.35 hours, AUC 4.97 +/- 1.09 microg-hr/ml for 50 mg (two pills) tab were observed.",Biopharmaceutical evaluation of oral tablet Atenolol (100 and 50 mg) on local population. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16431379/),[μg] / [ml],1.07,260794,DB00335,Atenolol
,16431379,Tmax,"Peak plasma concentration (Cmax): 1.33 +/- 0.31 microg/ml, time to peak plasma concentration (Tmax): 2.2 +/- 0.27 hours, AUC (area under the plasma concentration-time curve) 6.34 +/- 2.1 microg-hr/ml for 100 mg tab and Cmax: 1.07 +/- 0.23 microg/ml, Tmax: 2.5 +/- 0.35 hours, AUC 4.97 +/- 1.09 microg-hr/ml for 50 mg (two pills) tab were observed.",Biopharmaceutical evaluation of oral tablet Atenolol (100 and 50 mg) on local population. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16431379/),h,2.5,260795,DB00335,Atenolol
,16431379,AUC,"Peak plasma concentration (Cmax): 1.33 +/- 0.31 microg/ml, time to peak plasma concentration (Tmax): 2.2 +/- 0.27 hours, AUC (area under the plasma concentration-time curve) 6.34 +/- 2.1 microg-hr/ml for 100 mg tab and Cmax: 1.07 +/- 0.23 microg/ml, Tmax: 2.5 +/- 0.35 hours, AUC 4.97 +/- 1.09 microg-hr/ml for 50 mg (two pills) tab were observed.",Biopharmaceutical evaluation of oral tablet Atenolol (100 and 50 mg) on local population. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16431379/),[μg-hr] / [ml],4.97,260796,DB00335,Atenolol
,22886904,flow rate,"The chromatographic resolution was achieved on a Hypurity Advance C(18) column using an isocratic mobile phase consisting of 5 mm ammonium acetate-acetonitrile (15:85, v/v) at flow rate of 1.0 mL/min.",Sensitive LC-MS/MS-ESI method for simultaneous determination of nifedipine and atenolol in human plasma and its application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22886904/),[ml] / [min],1.0,264261,DB00335,Atenolol
,22886904,total run time of analysis,"The total run time of analysis was 2 min and elution of NF, AT and IS occurred at 0.79, 1.04 and 0.76 min, respectively.",Sensitive LC-MS/MS-ESI method for simultaneous determination of nifedipine and atenolol in human plasma and its application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22886904/),min,2,264262,DB00335,Atenolol
,2693499,half-life,"It has a half-life of 15-18 hours, and is demonstrated to be effective as an antihypertensive agent for 24-30 hours.",Dilevalol: a selective beta-2 adrenergic agonist vasodilator with beta adrenergic blocking activity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2693499/),h,15-18,265055,DB00335,Atenolol
,2566475,CSF/plasma ratio,The concentration of atenolol declined more slowly in CSF than in blood plasma and the CSF/plasma ratio of atenolol (after iv administration for 7 days) increased from 0.08 +/- 0.02 (2 hr after dose) to 0.83 +/- 0.14 (24 hr after dose) (mean +/- SD).,Central nervous system kinetics of atenolol and metoprolol in the dog during long term treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2566475/),,0.08,266297,DB00335,Atenolol
,2566475,CSF/plasma ratio,The concentration of atenolol declined more slowly in CSF than in blood plasma and the CSF/plasma ratio of atenolol (after iv administration for 7 days) increased from 0.08 +/- 0.02 (2 hr after dose) to 0.83 +/- 0.14 (24 hr after dose) (mean +/- SD).,Central nervous system kinetics of atenolol and metoprolol in the dog during long term treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2566475/),,0.83,266298,DB00335,Atenolol
,2566475,CSF/plasma ratio,The CSF/plasma ratio 24 hr after an iv dose was 0.48 +/- 0.12 on day 1 and 0.83 +/- 0.14 on day 7.,Central nervous system kinetics of atenolol and metoprolol in the dog during long term treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2566475/),,0.48,266299,DB00335,Atenolol
,2566475,CSF/plasma ratio,The CSF/plasma ratio 24 hr after an iv dose was 0.48 +/- 0.12 on day 1 and 0.83 +/- 0.14 on day 7.,Central nervous system kinetics of atenolol and metoprolol in the dog during long term treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2566475/),,0.83,266300,DB00335,Atenolol
,2566475,CSF/plasma ratio,"After 7 days of oral treatment, the CSF/plasma ratio of metoprolol 24 hr after dosing was 0.81 +/- 0.10.",Central nervous system kinetics of atenolol and metoprolol in the dog during long term treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2566475/),,0.81,266301,DB00335,Atenolol
,8068579,elimination half-life,"After oral administration the maximum concentration of moxonidine is reached in about 1 hour, and elimination half-life is 2.5 hours, prolonged by renal insufficiency.",Clinical experience with moxonidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8068579/),h,2.5,267059,DB00335,Atenolol
,19782235,analytical recovery,The analytical recovery of metoprolol from human plasma averaged 91.20%.,Gas chromatography-mass spectrometry method for determination of metoprolol in the patients with hypertension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19782235/),%,91.20,270295,DB00335,Atenolol
,19782235,limits of detection (LOD),"The limits of detection (LOD) and quantification (LOQ) of metoprolol were 5.0 and 15 ng/ml, respectively.",Gas chromatography-mass spectrometry method for determination of metoprolol in the patients with hypertension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19782235/),[ng] / [ml],5.0,270296,DB00335,Atenolol
,19782235,quantification (LOQ),"The limits of detection (LOD) and quantification (LOQ) of metoprolol were 5.0 and 15 ng/ml, respectively.",Gas chromatography-mass spectrometry method for determination of metoprolol in the patients with hypertension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19782235/),[ng] / [ml],15,270297,DB00335,Atenolol
,2439797,t1/2,"Monophasic elimination characteristics with t1/2 of 4.8 +/- 0.42 (prop), 6.87 +/- 0.46 (aten), and 9.19 +/- 0.38 h (biso) become apparent.","Concentration kinetics of propranolol, bisoprolol, and atenolol in humans assessed with chemical detection and a subtype-selective beta-adrenoceptor assay. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439797/),h,4.8,274170,DB00335,Atenolol
,2439797,t1/2,"Monophasic elimination characteristics with t1/2 of 4.8 +/- 0.42 (prop), 6.87 +/- 0.46 (aten), and 9.19 +/- 0.38 h (biso) become apparent.","Concentration kinetics of propranolol, bisoprolol, and atenolol in humans assessed with chemical detection and a subtype-selective beta-adrenoceptor assay. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439797/),h,6.87,274171,DB00335,Atenolol
,2439797,t1/2,"Monophasic elimination characteristics with t1/2 of 4.8 +/- 0.42 (prop), 6.87 +/- 0.46 (aten), and 9.19 +/- 0.38 h (biso) become apparent.","Concentration kinetics of propranolol, bisoprolol, and atenolol in humans assessed with chemical detection and a subtype-selective beta-adrenoceptor assay. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439797/),h,9.19,274172,DB00335,Atenolol
,2439797,maximum concentrations,"The maximum concentrations observed after administration of the doses mentioned previously were 220 +/- 71 (prop), 904 +/- 104 (aten), and 445 +/- 32 (biso) (ng/ml plasma).","Concentration kinetics of propranolol, bisoprolol, and atenolol in humans assessed with chemical detection and a subtype-selective beta-adrenoceptor assay. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439797/),[ng] / [ml],220,274173,DB00335,Atenolol
,2439797,maximum concentrations,"The maximum concentrations observed after administration of the doses mentioned previously were 220 +/- 71 (prop), 904 +/- 104 (aten), and 445 +/- 32 (biso) (ng/ml plasma).","Concentration kinetics of propranolol, bisoprolol, and atenolol in humans assessed with chemical detection and a subtype-selective beta-adrenoceptor assay. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439797/),[ng] / [ml],904,274174,DB00335,Atenolol
,2439797,maximum concentrations,"The maximum concentrations observed after administration of the doses mentioned previously were 220 +/- 71 (prop), 904 +/- 104 (aten), and 445 +/- 32 (biso) (ng/ml plasma).","Concentration kinetics of propranolol, bisoprolol, and atenolol in humans assessed with chemical detection and a subtype-selective beta-adrenoceptor assay. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439797/),[ng] / [ml],445,274175,DB00335,Atenolol
